Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	8.17e-08	14	171	5	GO:0008401
GeneOntologyMolecularFunction	semaphorin receptor activity	PLXND1 PLXNC1 PLXNA4 PLXNB3	2.44e-06	12	171	4	GO:0017154
GeneOntologyMolecularFunction	ABC-type transporter activity	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2	3.72e-06	49	171	6	GO:0140359
GeneOntologyMolecularFunction	ATP-dependent activity	ABCC3 ABCA13 MYO10 ATP10B HELQ DNAH14 ATP10D ABCB1 KIF9 ATP2C1 ABCA6 EIF4A2 DNAH17 ABCC12 CHD6 ABCC2 DHX29 DYNC1H1	5.74e-06	614	171	18	GO:0140657
GeneOntologyMolecularFunction	ATP hydrolysis activity	ABCC3 ABCA13 ATP10B HELQ ATP10D ABCB1 KIF9 ATP2C1 ABCA6 EIF4A2 ABCC12 CHD6 ABCC2 DHX29 DYNC1H1	6.28e-06	441	171	15	GO:0016887
GeneOntologyMolecularFunction	aromatase activity	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.15e-05	35	171	5	GO:0070330
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C8 CYP2C9 CYP3A5	3.35e-05	8	171	3	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C8 CYP2C9 CYP3A5	3.35e-05	8	171	3	GO:0034875
GeneOntologyMolecularFunction	ATPase-coupled transmembrane transporter activity	ABCC3 ABCA13 ABCB1 ATP2C1 ABCA6 ABCC12 ABCC2	4.27e-05	109	171	7	GO:0042626
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2C8 CYP2C9 CYP2C18 CYP2S1	4.83e-05	24	171	4	GO:0008392
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	6.11e-05	49	171	5	GO:0016712
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2C8 CYP2C9 CYP2C18 CYP2S1	7.81e-05	27	171	4	GO:0008391
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP2C8 CYP2C9 CYP3A5	9.68e-05	11	171	3	GO:0101020
GeneOntologyMolecularFunction	ribonucleoside triphosphate phosphatase activity	ABCC3 ABCA13 ATP10B HELQ ATP10D ABCB1 KIF9 ATP2C1 ABCA6 GNA13 EIF4A2 ABCC12 CHD6 GNAO1 ABCC2 DNM1 DHX29 DYNC1H1	1.22e-04	775	171	18	GO:0017111
GeneOntologyMolecularFunction	nucleocytoplasmic carrier activity	IPO4 CSE1L KPNB1 XPO7	1.55e-04	32	171	4	GO:0140142
GeneOntologyMolecularFunction	xenobiotic transmembrane transporter activity	ABCC3 SLC31A1 ABCB1 ABCC2	1.97e-04	34	171	4	GO:0042910
GeneOntologyMolecularFunction	glycosylceramide flippase activity	ATP10B ATP10D	2.18e-04	3	171	2	GO:0140351
GeneOntologyMolecularFunction	ABC-type xenobiotic transporter activity	ABCC3 ABCB1 ABCC2	2.60e-04	15	171	3	GO:0008559
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C8 CYP2C9 CYP3A5	2.60e-04	15	171	3	GO:0016725
GeneOntologyMolecularFunction	pyrophosphatase activity	ABCC3 ABCA13 ATP10B HELQ ATP10D ABCB1 KIF9 ATP2C1 ABCA6 GNA13 EIF4A2 ABCC12 CHD6 GNAO1 ABCC2 DNM1 DHX29 DYNC1H1	3.21e-04	839	171	18	GO:0016462
GeneOntologyMolecularFunction	hydrolase activity, acting on acid anhydrides	ABCC3 ABCA13 ATP10B HELQ ATP10D ABCB1 KIF9 ATP2C1 ABCA6 GNA13 EIF4A2 ABCC12 CHD6 GNAO1 ABCC2 DNM1 DHX29 DYNC1H1	3.26e-04	840	171	18	GO:0016817
GeneOntologyMolecularFunction	hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides	ABCC3 ABCA13 ATP10B HELQ ATP10D ABCB1 KIF9 ATP2C1 ABCA6 GNA13 EIF4A2 ABCC12 CHD6 GNAO1 ABCC2 DNM1 DHX29 DYNC1H1	3.26e-04	840	171	18	GO:0016818
GeneOntologyMolecularFunction	flippase activity	ATP10B ATP10D ABCB1	3.84e-04	17	171	3	GO:0140327
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C9 CYP2C18	4.33e-04	4	171	2	GO:0071614
GeneOntologyMolecularFunction	minus-end-directed microtubule motor activity	DNAH14 DNAH17 DYNC1H1	4.58e-04	18	171	3	GO:0008569
GeneOntologyMolecularFunction	sphingolipid transporter activity	ATP10B ATP10D ABCB1	6.32e-04	20	171	3	GO:0046624
GeneOntologyMolecularFunction	transporter activity	CACNA1D ABCC3 SCN11A SLC31A1 ABCA13 ATP10B ATP10D ABCB1 CUL5 SLC26A8 ATP2C1 KCNT2 KCNB1 CLCNKA NALCN ABCA6 KCNMA1 TMEM266 SLC36A3 ABCC12 ABCC2 LMBRD1 SLC44A3	6.58e-04	1289	171	23	GO:0005215
GeneOntologyMolecularFunction	primary active transmembrane transporter activity	ABCC3 ABCA13 ABCB1 ATP2C1 ABCA6 ABCC12 ABCC2	8.74e-04	178	171	7	GO:0015399
GeneOntologyMolecularFunction	dynein light intermediate chain binding	DNAH14 DNAH17 DYNC1H1	1.73e-03	28	171	3	GO:0051959
GeneOntologyMolecularFunction	ATPase-coupled intramembrane lipid transporter activity	ATP10B ATP10D ABCB1	1.73e-03	28	171	3	GO:0140326
GeneOntologyMolecularFunction	ABC-type glutathione S-conjugate transporter activity	ABCC3 ABCC2	1.97e-03	8	171	2	GO:0015431
GeneOntologyMolecularFunction	transmembrane transporter activity	CACNA1D ABCC3 SCN11A SLC31A1 ABCA13 ABCB1 CUL5 SLC26A8 ATP2C1 KCNT2 KCNB1 CLCNKA NALCN ABCA6 KCNMA1 TMEM266 SLC36A3 ABCC12 ABCC2 SLC44A3	2.74e-03	1180	171	20	GO:0022857
GeneOntologyMolecularFunction	tetrapyrrole binding	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 LMBRD1	2.92e-03	164	171	6	GO:0046906
GeneOntologyMolecularFunction	steroid hydroxylase activity	CYP2C8 CYP2C9 CYP3A5	3.04e-03	34	171	3	GO:0008395
GeneOntologyMolecularFunction	microtubule motor activity	DNAH14 KIF9 DNAH17 DYNC1H1	3.07e-03	70	171	4	GO:0003777
GeneOntologyMolecularFunction	monooxygenase activity	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.12e-03	115	171	5	GO:0004497
GeneOntologyMolecularFunction	ATPase-coupled inorganic anion transmembrane transporter activity	ABCC3 ABCC2	3.14e-03	10	171	2	GO:0043225
GeneOntologyMolecularFunction	cytoskeletal motor activity	MYO10 DNAH14 KIF9 DNAH17 DYNC1H1	3.49e-03	118	171	5	GO:0003774
GeneOntologyBiologicalProcess	xenobiotic metabolic process	ABCC3 CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 ABCB1 ABCC2	2.35e-05	141	171	8	GO:0006805
GeneOntologyBiologicalProcess	epoxygenase P450 pathway	CYP2C8 CYP2C9 CYP2C18 CYP2S1	2.97e-05	22	171	4	GO:0019373
GeneOntologyBiologicalProcess	spindle assembly	RIPOR2 CLASP1 TUBGCP6 WASHC5 CHEK2 STAG2 DYNC1H1 KPNB1	4.22e-05	153	171	8	GO:0051225
GeneOntologyCellularComponent	semaphorin receptor complex	PLXND1 PLXNC1 PLXNA4 PLXNB3	3.06e-06	13	173	4	GO:0002116
GeneOntologyCellularComponent	axonemal central pair projection	CFAP69 HYDIN	6.81e-05	2	173	2	GO:1990718
GeneOntologyCellularComponent	cerebellar climbing fiber to Purkinje cell synapse	ADGRB3 PLXNC1 PLXNA4	8.75e-05	11	173	3	GO:0150053
HumanPheno	Atypical absence seizure	ADGRV1 KCNT2 KCNB1 EIF4A2 KCNMA1 DNM1	1.63e-05	46	62	6	HP:0007270
MousePheno	decreased thermal nociceptive threshold	SCN11A FRMPD4 ADGRG1 CCDC141 TLR2 GNAO1	1.34e-05	54	136	6	MP:0003998
Domain	ARM-type_fold	MON2 MROH9 RIPOR2 CLASP1 NEK10 DOCK9 ARFGEF2 IPO4 URB1 CSE1L UTP20 HEATR5B CFAP69 UNC79 STAG2 KPNB1 XPO7	1.16e-08	339	168	17	IPR016024
Domain	ARM-like	MON2 MROH9 RIPOR2 CLASP1 NEK10 ARFGEF2 IPO4 CSE1L UTP20 HEATR5B CFAP69 STAG2 KPNB1 XPO7	1.60e-07	270	168	14	IPR011989
Domain	Plexin_cytopl	PLXND1 PLXNC1 PLXNA4 PLXNB3	7.68e-07	9	168	4	PF08337
Domain	Plexin_cytoplasmic_RasGAP_dom	PLXND1 PLXNC1 PLXNA4 PLXNB3	7.68e-07	9	168	4	IPR013548
Domain	Plexin	PLXND1 PLXNC1 PLXNA4 PLXNB3	7.68e-07	9	168	4	IPR031148
Domain	-	MON2 MROH9 RIPOR2 CLASP1 NEK10 ARFGEF2 IPO4 CSE1L UTP20 HEATR5B CFAP69 KPNB1	8.19e-07	222	168	12	1.25.10.10
Domain	ABC_tran	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2	4.35e-06	48	168	6	PF00005
Domain	ABC_TRANSPORTER_2	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2	4.35e-06	48	168	6	PS50893
Domain	ABC_TRANSPORTER_1	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2	4.92e-06	49	168	6	PS00211
Domain	ABC_transporter-like	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2	5.55e-06	50	168	6	IPR003439
Domain	IMPORTIN_B_NT	IPO4 CSE1L KPNB1 XPO7	5.89e-06	14	168	4	PS50166
Domain	IBN_N	IPO4 CSE1L KPNB1 XPO7	7.98e-06	15	168	4	PF03810
Domain	IBN_N	IPO4 CSE1L KPNB1 XPO7	1.06e-05	16	168	4	SM00913
Domain	Importin-beta_N	IPO4 CSE1L KPNB1 XPO7	1.37e-05	17	168	4	IPR001494
Domain	Cyt_P450_E_grp-I	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	5.07e-05	45	168	5	IPR002401
Domain	ABC_membrane	ABCC3 ABCB1 ABCC12 ABCC2	5.83e-05	24	168	4	PF00664
Domain	P-loop_NTPase	ABCC3 ABCA13 MYO10 SLFN5 HELQ URGCP DNAH14 ABCB1 KIF9 ABCA6 GNA13 EIF4A2 ABCC12 CHD6 GNAO1 ABCC2 DNM1 DHX29 HYDIN DYNC1H1	7.87e-05	848	168	20	IPR027417
Domain	IPT	PLXND1 PLXNC1 PLXNA4 PLXNB3	9.43e-05	27	168	4	SM00429
Domain	ABC_TM1F	ABCC3 ABCB1 ABCC12 ABCC2	1.09e-04	28	168	4	PS50929
Domain	ABC1_TM_dom	ABCC3 ABCB1 ABCC12 ABCC2	1.09e-04	28	168	4	IPR011527
Domain	Cyt_P450_CS	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.12e-04	53	168	5	IPR017972
Domain	-	ABCC3 ABCA13 SLFN5 HELQ URGCP DNAH14 ABCB1 ABCA6 GNA13 EIF4A2 ABCC12 CHD6 GNAO1 ABCC2 DNM1 DHX29 HYDIN DYNC1H1	1.38e-04	746	168	18	3.40.50.300
Domain	CYTOCHROME_P450	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.59e-04	57	168	5	PS00086
Domain	Channel_four-helix_dom	CACNA1D SCN11A KCNB1 NALCN TMEM266	1.59e-04	57	168	5	IPR027359
Domain	-	CACNA1D SCN11A KCNB1 NALCN TMEM266	1.59e-04	57	168	5	1.20.120.350
Domain	Semap_dom	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.64e-04	31	168	4	IPR001627
Domain	SEMA	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.64e-04	31	168	4	PS51004
Domain	TIG	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.64e-04	31	168	4	PF01833
Domain	Sema	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.64e-04	31	168	4	SM00630
Domain	Sema	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.64e-04	31	168	4	PF01403
Domain	-	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.73e-04	58	168	5	1.10.630.10
Domain	p450	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.73e-04	58	168	5	PF00067
Domain	IPT	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.87e-04	32	168	4	IPR002909
Domain	Plexin_repeat	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.87e-04	32	168	4	IPR002165
Domain	PSI	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.87e-04	32	168	4	PF01437
Domain	Cyt_P450	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	2.03e-04	60	168	5	IPR001128
Domain	AAA	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2 DYNC1H1	3.29e-04	144	168	7	SM00382
Domain	AAA+_ATPase	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2 DYNC1H1	3.29e-04	144	168	7	IPR003593
Domain	HEAT_REPEAT	CLASP1 IPO4 UTP20 HEATR5B KPNB1	4.19e-04	70	168	5	PS50077
Domain	HEAT_type_2	CLASP1 IPO4 KPNB1	4.43e-04	17	168	3	IPR021133
Domain	Pecanex_C	PCNX2 PCNX4	4.77e-04	4	168	2	PF05041
Domain	DCB_dom	MON2 ARFGEF2	4.77e-04	4	168	2	IPR032629
Domain	BK_channel_a	KCNT2 KCNMA1	4.77e-04	4	168	2	PF03493
Domain	Sec7_C	MON2 ARFGEF2	4.77e-04	4	168	2	IPR015403
Domain	DUF1981	MON2 ARFGEF2	4.77e-04	4	168	2	PF09324
Domain	K_chnl_Ca-activ_BK_asu	KCNT2 KCNMA1	4.77e-04	4	168	2	IPR003929
Domain	Sec7_N	MON2 ARFGEF2	4.77e-04	4	168	2	IPR032691
Domain	Multidrug-R_assoc	ABCC3 ABCC2	4.77e-04	4	168	2	IPR005292
Domain	Sec7_N	MON2 ARFGEF2	4.77e-04	4	168	2	PF12783
Domain	Pecanex	PCNX2 PCNX4	4.77e-04	4	168	2	IPR007735
Domain	DCB	MON2 ARFGEF2	4.77e-04	4	168	2	PF16213
Domain	ABC_transporter_CS	ABCC3 ABCB1 ABCC12 ABCC2	5.42e-04	42	168	4	IPR017871
Domain	Ion_trans_dom	CACNA1D SCN11A KCNB1 NALCN KCNMA1 TMEM266	5.80e-04	114	168	6	IPR005821
Domain	Ion_trans	CACNA1D SCN11A KCNB1 NALCN KCNMA1 TMEM266	5.80e-04	114	168	6	PF00520
Domain	PSI	PLXND1 PLXNC1 PLXNA4 PLXNB3	6.48e-04	44	168	4	IPR016201
Domain	PSI	PLXND1 PLXNC1 PLXNA4 PLXNB3	7.68e-04	46	168	4	SM00423
Domain	HEAT	CLASP1 IPO4 UTP20 KPNB1	9.03e-04	48	168	4	PF02985
Domain	Spectrin	SYNE1 CCDC141 DST	1.11e-03	23	168	3	PF00435
Domain	Rho_GTPase_activation_prot	PLXND1 PLXNC1 PLXNA4 ARHGAP20 PLXNB3	1.19e-03	88	168	5	IPR008936
Domain	HEAT	CLASP1 IPO4 UTP20 KPNB1	1.84e-03	58	168	4	IPR000357
Domain	Spectrin_repeat	SYNE1 CCDC141 DST	2.20e-03	29	168	3	IPR002017
Domain	Ig_E-set	A2M PLXND1 PLXNC1 PLXNA4 PLXNB3	2.49e-03	104	168	5	IPR014756
Domain	-	WDR25 PLXND1 ARHGEF17 PALB2 PLXNC1 UTP4 PLXNA4 RIC1 PLXNB3	3.25e-03	333	168	9	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	WDR25 PLXND1 ARHGEF17 PALB2 PLXNC1 UTP4 PLXNA4 RIC1 PLXNB3	3.38e-03	335	168	9	IPR015943
Domain	Hydrolase_3	ATP10B ATP10D	3.45e-03	10	168	2	PF08282
Domain	GPS	ADGRB3 ADGRG1 ADGRV1	3.49e-03	34	168	3	SM00303
Domain	GPS	ADGRB3 ADGRG1 ADGRV1	3.79e-03	35	168	3	PF01825
Domain	ATPase_P-typ_P_site	ATP10B ATP10D ATP2C1	4.11e-03	36	168	3	IPR018303
Domain	P_typ_ATPase	ATP10B ATP10D ATP2C1	4.11e-03	36	168	3	IPR001757
Domain	GPS	ADGRB3 ADGRG1 ADGRV1	4.11e-03	36	168	3	PS50221
Domain	ATPASE_E1_E2	ATP10B ATP10D ATP2C1	4.11e-03	36	168	3	PS00154
Domain	ATPase_P-typ_transduc_dom_A	ATP10B ATP10D ATP2C1	4.44e-03	37	168	3	IPR008250
Domain	GPS	ADGRB3 ADGRG1 ADGRV1	4.44e-03	37	168	3	IPR000203
Domain	E1-E2_ATPase	ATP10B ATP10D ATP2C1	4.44e-03	37	168	3	PF00122
Domain	ABC_A	ABCA13 ABCA6	5.00e-03	12	168	2	IPR026082
Domain	Dynein_heavy_chain_D4_dom	DNAH14 DYNC1H1	6.82e-03	14	168	2	IPR024317
Domain	Dynein_HC_stalk	DNAH14 DYNC1H1	6.82e-03	14	168	2	IPR024743
Domain	P_typ_ATPase_c	ATP10B ATP10D	6.82e-03	14	168	2	IPR032630
Domain	P-type_ATPase_N	ATP10B ATP10D	6.82e-03	14	168	2	IPR032631
Domain	P-type_ATPase_IV	ATP10B ATP10D	6.82e-03	14	168	2	IPR006539
Domain	MT	DNAH14 DYNC1H1	6.82e-03	14	168	2	PF12777
Domain	AAA_8	DNAH14 DYNC1H1	6.82e-03	14	168	2	PF12780
Domain	PhoLip_ATPase_C	ATP10B ATP10D	6.82e-03	14	168	2	PF16212
Domain	PhoLip_ATPase_N	ATP10B ATP10D	6.82e-03	14	168	2	PF16209
Domain	DHC_fam	DNAH14 DYNC1H1	7.82e-03	15	168	2	IPR026983
Domain	Dynein_heavy	DNAH14 DYNC1H1	7.82e-03	15	168	2	PF03028
Domain	Dynein_heavy_dom	DNAH14 DYNC1H1	7.82e-03	15	168	2	IPR004273
Domain	GproteinA_insert	GNA13 GNAO1	8.88e-03	16	168	2	IPR011025
Domain	-	GNA13 GNAO1	8.88e-03	16	168	2	1.10.400.10
Domain	G-alpha	GNA13 GNAO1	8.88e-03	16	168	2	PF00503
Domain	G_alpha	GNA13 GNAO1	8.88e-03	16	168	2	SM00275
Pathway	REACTOME_XENOBIOTICS	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.27e-06	23	121	5	M5372
Pathway	KEGG_ABC_TRANSPORTERS	ABCC3 ABCA13 ABCB1 ABCA6 ABCC12 ABCC2	1.91e-06	44	121	6	M11911
Pathway	WP_CODEINE_AND_MORPHINE_METABOLISM	ABCC3 CYP2C8 ABCB1 ABCC2	4.84e-06	14	121	4	M39328
Pathway	WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY	ABCC3 CYP2C9 CYP3A5 ABCB1 ABCC2	6.09e-06	31	121	5	M39476
Pathway	WP_PREGNANE_X_RECEPTOR_PATHWAY	ABCC3 CYP2C9 CYP3A5 ABCB1 ABCC2	7.17e-06	32	121	5	M39567
Pathway	REACTOME_OTHER_SEMAPHORIN_INTERACTIONS	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.81e-05	19	121	4	M10959
Pathway	REACTOME_XENOBIOTICS	CYP2C8 CYP2C9 CYP3A5 CYP2S1	5.68e-05	25	121	4	MM14846
Pathway	REACTOME_CYP2E1_REACTIONS	CYP2C8 CYP2C9 CYP2S1	9.68e-05	11	121	3	M27130
Pathway	KEGG_LINOLEIC_ACID_METABOLISM	CYP2C8 CYP2C9 CYP2C18 CYP3A5	1.04e-04	29	121	4	M2920
Pathway	WP_ENTEROHEPATIC_CIRCULATION_OF_BILE_ACIDS	ABCC3 ABCB1 ABCC2	1.28e-04	12	121	3	M48096
Pathway	BIOCARTA_NUCLEARRS_PATHWAY	ABCC3 CYP3A5 ABCB1 ABCC2	1.74e-04	33	121	4	MM1448
Pathway	WP_OXIDATION_BY_CYTOCHROME_P450	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.88e-04	62	121	5	M39653
Pathway	BIOCARTA_NUCLEARRS_PATHWAY	ABCC3 CYP2C9 ABCB1 ABCC2	1.96e-04	34	121	4	M16393
Pathway	REACTOME_OTHER_SEMAPHORIN_INTERACTIONS	PLXND1 PLXNC1 PLXNB3	2.10e-04	14	121	3	MM15047
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	2.18e-04	64	121	5	M5650
Pathway	WP_NUCLEAR_RECEPTORS_IN_LIPID_METABOLISM_AND_TOXICITY	ABCC3 CYP2C9 ABCB1 ABCC2	2.20e-04	35	121	4	M39488
Pathway	REACTOME_ATORVASTATIN_ADME	CYP3A5 ABCB1 ABCC2	2.60e-04	15	121	3	MM15697
Pathway	KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.32e-04	70	121	5	M16794
Pathway	WP_DRUG_INDUCTION_OF_BILE_ACID_PATHWAY	ABCC3 ABCB1 ABCC2	3.84e-04	17	121	3	M39666
Pathway	REACTOME_ASPIRIN_ADME	ABCC3 CYP2C8 CYP2C9 ABCC2	5.38e-04	44	121	4	M45014
Pathway	REACTOME_ASPIRIN_ADME	ABCC3 CYP2C8 CYP3A5 ABCC2	5.86e-04	45	121	4	MM15694
Pathway	BIOCARTA_MRP_PATHWAY	ABCC3 ABCB1	7.18e-04	5	121	2	MM1586
Pathway	WP_TAMOXIFEN_METABOLISM	CYP2C8 CYP2C9 CYP3A5	7.33e-04	21	121	3	M39631
Pathway	REACTOME_SEMAPHORIN_INTERACTIONS	PLXND1 PLXNC1 PLXNA4 PLXNB3	9.45e-04	51	121	4	MM14967
Pathway	BIOCARTA_MRP_PATHWAY	ABCC3 ABCB1	1.07e-03	6	121	2	M22078
Pathway	REACTOME_BIOSYNTHESIS_OF_MARESIN_LIKE_SPMS	CYP2C8 CYP2C9	1.07e-03	6	121	2	M27909
Pathway	WP_ESTROGEN_METABOLISM_WP5276	CYP2C8 CYP2C9 CYP3A5	1.09e-03	24	121	3	M46445
Pubmed	E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins.	MROH9 CCDC73 COL28A1 VPS13C CEP290 SLFN5 LRRC70 ARHGEF17 DNAH14 FRY URB1 DST PLXNA4 UTP20 SNX31 LRRC7 CHD6 ARHGAP20 DYNC1H1 PLXNB3	8.32e-10	736	172	20	29676528
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	MON2 RIPOR2 FRMPD4 CLASP1 MYO10 SYNE1 DOCK9 ARHGEF17 ERBIN SUGP2 LRRC7 CHD6 DYNC1H1 PLXNB3 XPO7	2.15e-09	407	172	15	12693553
Pubmed	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.	CYP2C8 CYP2C9 ABCB1 ABCC2	2.88e-09	5	172	4	19415824
Pubmed	Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.	CYP2C8 CYP2C9 CYP3A5 ABCB1	8.60e-09	6	172	4	17635176
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	CLASP1 KDM5A SYNE1 ADGRB3 IPO4 ERBIN NEK9 CEP170 FRY DST TRIM67 KCNB1 SYNJ1 EIF4A2 KCNMA1 LRRC7 GNAO1 DNM1 UNC79 DYNC1H1 KPNB1	1.47e-08	963	172	21	28671696
Pubmed	Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro.	VPS13C ATP2C1 LRRC7 CHD6 HEATR5B ARHGAP20 UNC79 ZMYM6 RIC1	7.77e-08	153	172	9	10718198
Pubmed	Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons.	MON2 RIPOR2 CLASP1 PSMD8 IPO4 TMX2 CSE1L DST PCNX4 DNM1 DYNC1H1 KPNB1	8.16e-08	322	172	12	26514267
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	SLC31A1 VPS13C ADGRG1 WDR25 ADGRV1 ERBIN NEK9 DNAH14 FAF1 CUL5 PCNX2 CEP170 ATP2C1 SUGP2 PCNX4 PLEKHG3 KCNMA1 LRRC7 CHD6 CFAP69 PCCA STAG2 RIC1 DOP1A XPO7	9.46e-08	1489	172	25	28611215
Pubmed	The human CYP2C locus: a prototype for intergenic and exon repetition splicing events.	CYP2C8 CYP2C9 CYP2C18	1.19e-07	3	172	3	10704292
Pubmed	Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.	CYP2C9 CYP3A5 ABCB1	1.19e-07	3	172	3	14676821
Pubmed	Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.	CYP2C8 CYP2C9 CYP3A5 ABCB1 ABCC2	2.06e-07	27	172	5	20173083
Pubmed	Overlapping Activities of Two Neuronal Splicing Factors Switch the GABA Effect from Excitatory to Inhibitory by Regulating REST.	NRBP1 CACNA1D CLASP1 VPS13C DOCK9 SYNJ1 KCNMA1 DOP1A	2.62e-07	128	172	8	30995482
Pubmed	Transmembrane semaphorin signalling controls laminar stratification in the mammalian retina.	PLXND1 PLXNC1 PLXNA4 PLXNB3	2.77e-07	12	172	4	21270798
Pubmed	Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.	CYP2C9 CYP3A5 ABCB1 ABCC2	3.99e-07	13	172	4	16771603
Pubmed	Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates.	PLXND1 PLXNC1 PLXNA4 PLXNB3	3.99e-07	13	172	4	10520995
Pubmed	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.	CYP2C8 CYP3A5 ABCB1	4.74e-07	4	172	3	16299241
Pubmed	Biochemistry and molecular biology of the human CYP2C subfamily.	CYP2C8 CYP2C9 CYP2C18	4.74e-07	4	172	3	7704034
Pubmed	Regulation of mRNA expression of MDR1, MRP1, MRP2 and MRP3 by prototypical microsomal enzyme inducers in primary cultures of human and rat hepatocytes.	ABCC3 ABCB1 ABCC2	4.74e-07	4	172	3	16946557
Pubmed	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	CYP2C8 CYP2C9 CYP2C18	4.74e-07	4	172	3	19706858
Pubmed	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.	CYP2C8 CYP3A5 ABCB1	4.74e-07	4	172	3	15961978
Pubmed	The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers.	ABCC3 ABCB1 ABCC2	4.74e-07	4	172	3	28408210
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.	CYP2C8 CYP2C9 CYP2C18	4.74e-07	4	172	3	2009263
Pubmed	Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.	ABCC3 ABCB1 ABCC2	4.74e-07	4	172	3	25162314
Pubmed	Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.	CYP2C8 CYP3A5 ABCB1	4.74e-07	4	172	3	17701008
Pubmed	Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.	CYP2C8 CYP2C9 CYP2C18	4.74e-07	4	172	3	21798861
Pubmed	Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.	CYP3A5 ABCB1 ABCC2	4.74e-07	4	172	3	19865079
Pubmed	Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells.	ABCC3 ABCB1 ABCC2	4.74e-07	4	172	3	19956884
Pubmed	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.	CYP2C8 CYP2C9 CYP2C18	4.74e-07	4	172	3	23755828
Pubmed	Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa.	CYP2C8 CYP2C9 CYP3A5	4.74e-07	4	172	3	16253141
Pubmed	Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.	CYP2C8 CYP2C9 CYP2C18 CYP3A5	5.56e-07	14	172	4	19290787
Pubmed	Toward personalized medicine in renal transplantation.	CYP2C8 CYP2C9 CYP3A5 ABCB1	5.56e-07	14	172	4	20970553
Pubmed	Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.	CYP2C8 CYP3A5 ABCB1 ABCC2	1.00e-06	16	172	4	17925548
Pubmed	Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip.	CYP2C8 CYP2C9 CYP3A5 ABCB1	1.00e-06	16	172	4	20136364
Pubmed	Pharmacogenetic pathway analysis of docetaxel elimination.	CYP3A5 ABCB1 ABCC2	1.18e-06	5	172	3	18509327
Pubmed	Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.	CYP2C9 ABCB1 ABCC2	1.18e-06	5	172	3	20102361
Pubmed	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.	CYP2C8 CYP2C18 CYP3A5	1.18e-06	5	172	3	11093772
Pubmed	CYP2C192 and CYP2C93 alleles are associated with stent thrombosis: a case-control study.	CYP2C9 CYP3A5 ABCB1	1.18e-06	5	172	3	20833683
Pubmed	Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues.	CYP2C8 CYP2C18 CYP3A5	1.18e-06	5	172	3	9797707
Pubmed	Plexin-A3 mediates semaphorin signaling and regulates the development of hippocampal axonal projections.	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.31e-06	17	172	4	11683995
Pubmed	Semaphorin signaling facilitates cleft formation in the developing salivary gland.	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.31e-06	17	172	4	17626059
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	SYNE1 DOCK9 ADGRB3 ADGRV1 ERBIN URB1 DST SYNJ1 CHD6	1.99e-06	225	172	9	12168954
Pubmed	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.	CYP2C9 CYP3A5 ABCB1	2.35e-06	6	172	3	20179710
Pubmed	Besides CYP2C192, the variant allele CYP2C93 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.	CYP2C9 CYP3A5 ABCB1	2.35e-06	6	172	3	19934793
Pubmed	Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.	CYP2C8 CYP3A5 ABCB1	2.35e-06	6	172	3	20212519
Pubmed	Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.	CYP3A5 ABCB1 ABCC2	2.35e-06	6	172	3	20720558
Pubmed	Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.	CYP3A5 ABCB1 ABCC2	2.35e-06	6	172	3	16791115
Pubmed	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.	CYP3A5 ABCB1 ABCC2	2.35e-06	6	172	3	18192894
Pubmed	Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.	CYP3A5 ABCB1 ABCC2	2.35e-06	6	172	3	21351274
Pubmed	A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.	CYP3A5 ABCB1 ABCC2	2.35e-06	6	172	3	18518855
Pubmed	Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.	CYP2C9 CYP3A5 ABCB1	2.35e-06	6	172	3	16595916
Pubmed	Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.	CYP3A5 ABCB1 ABCC2	2.35e-06	6	172	3	15801936
Pubmed	Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics.	SYNE1 DST DNAH17 HEATR5B	2.63e-06	20	172	4	21689717
Pubmed	Molecular genetics of the human cytochrome P450 monooxygenase superfamily.	CYP2C8 CYP2C9 CYP2C18 CYP3A5	2.63e-06	20	172	4	9890157
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	UTP6 SYNE1 CEP290 ABCB1 CEP170 URB1 CSE1L DST SUGP2 PLEKHG3 GNA13 UTP4 UTP20 HEATR5B STAG2 DYNC1H1 KPNB1 XPO7	3.64e-06	1024	172	18	24711643
Pubmed	Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.	CYP3A5 ABCB1 ABCC2	4.10e-06	7	172	3	18294295
Pubmed	Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.	CYP2C8 CYP3A5 ABCB1	4.10e-06	7	172	3	19470925
Pubmed	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.	CYP3A5 ABCB1 ABCC2	4.10e-06	7	172	3	19842932
Pubmed	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.	CYP3A5 ABCB1 ABCC2	4.10e-06	7	172	3	18221820
Pubmed	Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.	ABCC3 ABCB1 ABCC2	4.10e-06	7	172	3	20922799
Pubmed	LMBR1L regulates lymphopoiesis through Wnt/β-catenin signaling.	UTP6 GPS1 PSMD8 IPO4 URGCP FAF1 URB1 ATP2C1 CSE1L FAM20B UTP20 HEATR5B VPS53 STAG2 DYNC1H1 KPNB1 XPO7	4.88e-06	942	172	17	31073040
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	UTP6 IPO4 ZCCHC3 CEP170 URB1 CSE1L DST SUGP2 UTP4 UTP20 STAG2 DYNC1H1 KPNB1 XPO7	5.13e-06	653	172	14	22586326
Pubmed	Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.	ABCC3 CYP2C8 CYP2C9 CYP3A5 CYP2S1 ABCB1 ABCA6 ABCC2	5.76e-06	193	172	8	19343046
Pubmed	The expression of plexins during mouse embryogenesis.	PLXNC1 PLXNA4 PLXNB3	6.54e-06	8	172	3	15661641
Pubmed	Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice.	ABCC3 ABCC12 ABCC2	6.54e-06	8	172	3	15802388
Pubmed	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.	CYP2C9 CYP3A5 ABCB1	6.54e-06	8	172	3	20147896
Pubmed	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.	CYP2C9 CYP3A5 ABCB1	6.54e-06	8	172	3	19593168
Pubmed	Analysis of the sperm flagellar axoneme using gene-modified mice.	KIF9 CFAP54 CFAP69	6.54e-06	8	172	3	32554934
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	SH3TC2 CEP290 NEK9 CEP170 ZBTB34 ZNF836 ATP2C1 PLEKHG3 UTP4 DNAH17 RIC1 DOP1A	7.03e-06	493	172	12	15368895
Pubmed	ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.	CYP2C9 CYP3A5 ABCB1	9.77e-06	9	172	3	17178267
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	SCN11A KDM5A SYNE1 GPS1 ATP10B PSMD8 ERBIN PALB2 ABCB1 DST TRIM67 GNA13 EIF4A2 PLXNA4 CHD6 GNAO1 ABCC2 CFAP69 STAG2 DOP1A KPNB1	9.98e-06	1442	172	21	35575683
Pubmed	An evaluation of the assembly of an approximately 15-Mb region on human chromosome 13q32-q33 linked to bipolar disorder and schizophrenia.	GPR18 DOCK9 NALCN PCCA	1.25e-05	29	172	4	11991713
Pubmed	Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.	RIPOR2 FRMPD4 CEP290 ARHGEF17 SUGP2 DYNC1H1	1.36e-05	104	172	6	9205841
Pubmed	Pharmacogenetically relevant polymorphisms in Portugal.	CYP2C9 CYP3A5 ABCB1	1.39e-05	10	172	3	18240903
Pubmed	Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.	CYP2C8 CYP2C9 ABCB1	1.39e-05	10	172	3	20602612
Pubmed	Irinotecan pathway genotype analysis to predict pharmacokinetics.	CYP3A5 ABCB1 ABCC2	1.39e-05	10	172	3	12960109
Pubmed	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.	CYP2C8 CYP2C9 CYP3A5	1.39e-05	10	172	3	12865317
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	VPS13C ADGRB3 PLXND1 ADGRV1 URGCP TUBGCP6 DST WASHC5 FAM20B TMEM131L ARHGAP20 HERC4	1.42e-05	529	172	12	14621295
Pubmed	Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE.	CYP2C8 CYP2C9 CYP2C18 CYP3A5	1.43e-05	30	172	4	20529763
Pubmed	Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.	CYP2C8 CYP2C9 CYP3A5 ABCB1	1.64e-05	31	172	4	20031551
Pubmed	Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.	CYP2C8 CYP2C9 CYP3A5	1.90e-05	11	172	3	15469410
Pubmed	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.	CYP2C8 CYP2C9 CYP3A5	1.90e-05	11	172	3	15039299
Pubmed	Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.	CYP2C8 CYP3A5 ABCB1	1.90e-05	11	172	3	20389299
Pubmed	Gene essentiality and synthetic lethality in haploid human cells.	ATP2C1 TXNDC15 COG6 PTAR1 TMEM131L VPS53 RIC1 KPNB1	1.99e-05	229	172	8	26472760
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	NRBP1 KDM5A SYNE1 CEP290 ADGRB3 ARFGEF2 FAF1 ZNF836 FRY TXNDC15 DST SYNJ1 EIF4A2 MIGA1 CHD6 DNM1 DYNC1H1 PLXNB3 KPNB1	2.21e-05	1285	172	19	35914814
Pubmed	Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform.	CYP2C8 CYP2C9	2.43e-05	2	172	2	7574697
Pubmed	The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.	CYP3A5 ABCB1	2.43e-05	2	172	2	25590378
Pubmed	Quantitative Assessment of the Association between ABC Polymorphisms and Osteosarcoma Response: a Meta-analysis.	ABCC3 ABCB1	2.43e-05	2	172	2	26107220
Pubmed	Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative.	CYP2C8 CYP2C9	2.43e-05	2	172	2	30562214
Pubmed	Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.	CYP2C8 CYP2C9	2.43e-05	2	172	2	26122864
Pubmed	Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.	ABCC3 ABCB1	2.43e-05	2	172	2	22016816
Pubmed	Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.	CYP3A5 ABCB1	2.43e-05	2	172	2	25869250
Pubmed	Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.	ABCB1 ABCC2	2.43e-05	2	172	2	21864659
Pubmed	CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.	CYP3A5 ABCB1	2.43e-05	2	172	2	21076384
Pubmed	CYP3A53 and CYP2C83 variants influence exposure and clinical outcomes of tacrolimus-based therapy.	CYP2C8 CYP3A5	2.43e-05	2	172	2	31849280
Pubmed	Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.	ABCB1 ABCC2	2.43e-05	2	172	2	21039333
Pubmed	Frequency of ABCB1 C3435T and CYP3A5*3 Genetic Polymorphisms in the Lebanese Population.	CYP3A5 ABCB1	2.43e-05	2	172	2	34053421
Pubmed	Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.	CYP2C8 CYP2C9	2.43e-05	2	172	2	12435384
Pubmed	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.	CYP2C8 CYP2C9	2.43e-05	2	172	2	18694831
Pubmed	Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.	CYP3A5 ABCB1	2.43e-05	2	172	2	26421491
Pubmed	Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.	CYP2C9 CYP3A5	2.43e-05	2	172	2	18597650
Interaction	NPTN interactions	MON2 MMS22L ARFGEF2 IPO4 CSE1L TRIM67 COG6 UTP20 GNAO1 HEATR5B STAG2 DOP1A XPO7	6.69e-07	278	169	13	int:NPTN
Interaction	GPR17 interactions	MMS22L ARFGEF2 URB1 CSE1L COG6 GNA13 UTP20 MIGA1 HEATR5B VPS53 STAG2 DOP1A XPO7	8.18e-07	283	169	13	int:GPR17
Interaction	MTNR1B interactions	MON2 RIPOR2 CLASP1 PSMD8 IPO4 CSE1L DST PCNX4 DYNC1H1	2.10e-06	135	169	9	int:MTNR1B
Interaction	SCN11A interactions	CACNA1D SCN11A ATP2C1 NALCN	6.06e-06	15	169	4	int:SCN11A
Interaction	PTAR1 interactions	TXNDC15 TRIM67 COG6 PTAR1 TMEM131L VPS53 RIC1	8.56e-06	87	169	7	int:PTAR1
Interaction	CD70 interactions	SLC31A1 CYP2S1 CSE1L WASHC5 UTP20 MIGA1 DNM1 STAG2 XPO7	1.14e-05	166	169	9	int:CD70
Interaction	ARMH3 interactions	TRIM67 COG6 PTAR1 VPS53 RIC1	1.19e-05	36	169	5	int:ARMH3
Interaction	GYPA interactions	UTP6 CLASP1 CYP2S1 DSN1 UTP20 MIGA1 DNM1 STAG2 XPO7	1.66e-05	174	169	9	int:GYPA
Interaction	RNF123 interactions	MROH9 CCDC73 COL28A1 VPS13C CEP290 SLFN5 LRRC70 ARHGEF17 DNAH14 FRY URB1 DST PLXNA4 UTP20 SNX31 LRRC7 CHD6 ARHGAP20 DYNC1H1 PLXNB3	2.00e-05	824	169	20	int:RNF123
Interaction	SCN9A interactions	CACNA1D SCN11A ATP2C1 NALCN	2.56e-05	21	169	4	int:SCN9A
Interaction	GPR182 interactions	MON2 MMS22L UBE3B ARFGEF2 ADGRG1 CYP2S1 URB1 ATP2C1 CSE1L WASHC5 CHEK2 UTP20 VPS53 XPO7	3.10e-05	455	169	14	int:GPR182
Interaction	EFNA4 interactions	NEK10 URB1 COG6 WASHC5 UTP20 DNM1 HEATR5B VPS53 STAG2 XPO7	3.51e-05	239	169	10	int:EFNA4
Interaction	CACNA1D interactions	CACNA1D SCN11A KCNB1 NALCN	4.45e-05	24	169	4	int:CACNA1D
Interaction	PACC1 interactions	MMS22L ATP2C1 CSE1L TRIM67 GNA13 MIGA1 XPO7	6.56e-05	119	169	7	int:PACC1
Interaction	OPALIN interactions	MON2 ARFGEF2 SLFN5 CYP2S1 ATP2C1 CSE1L UTP20 ABCC2 XPO7	6.97e-05	209	169	9	int:OPALIN
Interaction	CYP2C18 interactions	A2M CYP2C8 CYP2C9 CYP2C18	7.20e-05	27	169	4	int:CYP2C18
Interaction	OBP2A interactions	ERBIN TXNDC15 CLN5	9.10e-05	11	169	3	int:OBP2A
Cytoband	13q32	GPR18 GPC5 PCCA	1.46e-05	13	173	3	13q32
Cytoband	10q24	CYP2C9 CYP2C18 ABCC2	3.15e-04	35	173	3	10q24
GeneFamily	Plexins	PLXND1 PLXNC1 PLXNA4 PLXNB3	1.91e-07	9	115	4	683
GeneFamily	ATP binding cassette subfamily C	ABCC3 ABCC12 ABCC2	6.84e-05	13	115	3	807
GeneFamily	Cytochrome P450 family 2	CYP2C8 CYP2C9 CYP2C18 CYP2S1	6.98e-05	35	115	4	1001
GeneFamily	Exportins	CSE1L XPO7	8.25e-04	7	115	2	547
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CACNA1D FRMPD4 SYNE1 ADGRB3 FRY KCNB1 KCNMA1 LRRC7 DNM1 UNC79	5.91e-09	198	173	10	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 COL28A1 SYNE1 MUC16 CFAP54 CCDC180 CFAP69 HYDIN	7.21e-08	194	173	9	4a2c127c90d1fefe604fcb9e796577d21b489dd6
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CACNA1D FRMPD4 SYNE1 ADGRB3 FRY KCNB1 LRRC7 DNM1 UNC79	7.87e-08	196	173	9	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NEK10 SYNE1 CEP290 LRRC9 CFAP54 KCNB1 CCDC180 CFAP69 HYDIN	8.22e-08	197	173	9	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CACNA1D FRMPD4 SYNE1 FRY KCNB1 KCNMA1 LRRC7 DNM1 UNC79	8.58e-08	198	173	9	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2C9 ABCA13 MUC16 ATP10B ADGRV1 CAPN8 URB1 CATSPERB	5.18e-07	179	173	8	6e965e424eebef50f0202cff75f458be395cfca1
ToppCell	COVID-19-kidney-Epi_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	ABCC3 CYP3A5 SYNE1 FRY CFAP54 DST KCNT2 DNM1	5.18e-07	179	173	8	e7c9dc63f03d3f3746b51a7e3c8393089e2ceb7d
ToppCell	10x5'-lymph-node_spleen-Myeloid_Mac-Intestinal_macrophages\|lymph-node_spleen / Manually curated celltypes from each tissue	A2M ABCC3 P2RY13 DST TLR2 KCNMA1 ECEL1 CMKLR1	5.41e-07	180	173	8	7be7d7a6906fff6dbdecd9cb013d855aba4eda2a
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	MON2 A2M TTC39B MMS22L CLASP1 VPS13C URB1 TMEM131L	6.93e-07	186	173	8	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ABCC3 ABCA13 COL28A1 SYNE1 DNAH14 CAPN8 CFAP54 HYDIN	8.13e-07	190	173	8	3fc9e18c7441c0ae8cda65753cc42d0520f4e116
ToppCell	Dendritic_cell\|World / shred by cell class for nasal brushing	A2M P2RY13 PLXND1 FCER1A KCNMA1 GNAO1 CMKLR1 NCKAP1L	8.13e-07	190	173	8	ae24934f45eea9c228bf6fe8cd0d6abca9eb208e
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CACNA1D FRMPD4 SYNE1 ADGRB3 ABCA6 CHEK2 PLXNA4 ARHGAP20	9.52e-07	194	173	8	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CACNA1D FRMPD4 ADGRB3 ABCA6 PLXNA4 LRRC7 ARHGAP20 CFAP69	9.52e-07	194	173	8	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ABCA13 ADGRB3 MUC16 ADGRV1 DNAH14 TRIM67 KCNB1 ABCC12	9.89e-07	195	173	8	d3755929ebbbf5e3afde44281e9056ddb614a291
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ABCA13 ADGRB3 MUC16 ADGRV1 DNAH14 TRIM67 KCNB1 ABCC12	9.89e-07	195	173	8	19853c654ac64b3ae3bc99841c6cb29c8aaba85c
ToppCell	COVID-19_Severe-Lymphoid_T/NK-gd_T\|COVID-19_Severe / Disease group, lineage and cell class	A2M RIPOR2 SYNE1 ADGRG1 SLFN5 ERBIN ABCB1 PLEKHG3	9.89e-07	195	173	8	9990440bda7fac5d00ef80444fab07459be625e1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	A2M RIPOR2 SYNE1 ADGRG1 SLFN5 ERBIN ABCB1 PLEKHG3	1.03e-06	196	173	8	418e8e0a51c5cb60e3b903e7d2d800dc8b9f3d5c
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M RIPOR2 SYNE1 ADGRG1 SLFN5 ERBIN ABCB1 PLEKHG3	1.03e-06	196	173	8	581fc8c8d42005aacd7b401a2c9d1fc331fb4af7
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	A2M RIPOR2 SYNE1 ADGRG1 SLFN5 ERBIN ABCB1 PLEKHG3	1.03e-06	196	173	8	6beaf0c2799424c59819b286fbb5c1a83d85e4d1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M RIPOR2 SYNE1 ADGRG1 SLFN5 ERBIN ABCB1 PLEKHG3	1.03e-06	196	173	8	c35f2349dfe35baa845f790b9f31673dceac54c0
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	CACNA1D ABCC3 MYO10 ADGRB3 DST ABCA6 PTAR1 ARHGAP20	1.07e-06	197	173	8	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	CACNA1D FRMPD4 SYNE1 FRY KCNB1 LRRC7 DNM1 UNC79	1.20e-06	200	173	8	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	facs-Lung-Endomucin-24m-Endothelial-Capillary_Type_1_Cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRMPD4 PTTG1IP2 ABCA13 ADGRV1 LRRC7 ABCC2 HYDIN	1.63e-06	145	173	7	96712c68ab759d7ade0d912581a1a7c25dc6def8
ToppCell	lung-Ciliated_Epithelia\|lung / shred on tissue and cell subclass	NEK10 MUC16 KIF9 CFAP54 PCNX4 CCDC180 CFAP69	4.15e-06	167	173	7	26cf1cfa58ee74794449a87eb19cd896e1ec8892
ToppCell	ileum\|World / shred on tissue and cell subclass	CYP2C18 KDM5A CYP3A5 ABCB1 DST ABCC2 BAIAP2L2	4.67e-06	170	173	7	9f1211bd4287620e19a59f21e6ecdca3e42e0260
ToppCell	Dendritic_Cells-Cryobiopsy_01\|World / lung cells shred on cell class, cell subclass, sample id	P2RY13 CYP2S1 FCER1A ABCA6 PLXNC1 GNAO1 DNM1	6.09e-06	177	173	7	d2cd081bdda0eba9f6f6473c4d3939e4bee3440e
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	RIPOR2 ABCA13 ATP10B ABCB1 CFAP54 KCNT2 HYDIN	7.05e-06	181	173	7	6956ecd6264f7469a25e555673bce4eb97d28f7a
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	A2M CACNA1D CYP3A5 MYO10 ADGRB3 ABCA6 MUSK	7.05e-06	181	173	7	9ede19228ba5c0668a9c06c915510b95585216ef
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_OPALIN\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 ATP10B NEK3 PLEKHG3 FAM124A MUSK PLXNB3	7.57e-06	183	173	7	5472cdce6d99314d229418412acf1fff6340db7d
ToppCell	COVID-19_Mild-NK_activated\|COVID-19_Mild / Disease condition and Cell class	RIPOR2 SYNE1 ADGRG1 ERBIN PCNX4 TMEM131L CMKLR1	7.57e-06	183	173	7	22bd05135906d0ecc4ba8c2e0a666093d1bf3b8f
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M FRMPD4 ABCA13 ADGRV1 CAPN8 UNC79 HYDIN	7.84e-06	184	173	7	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 ATP10B NEK3 PLEKHG3 FAM124A MUSK PLXNB3	7.84e-06	184	173	7	5939527d24d299e562e707469c9123890edd76be
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	THBS2 KCNT2 NALCN ABCA6 LRRC7 GNAO1 ARHGAP20	7.84e-06	184	173	7	e061e85c4bb19f49f6451ddd7a9077d7378ee365
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M FRMPD4 ABCA13 ADGRV1 CAPN8 UNC79 HYDIN	7.84e-06	184	173	7	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	A2M FRMPD4 ABCA13 ADGRV1 CAPN8 UNC79 HYDIN	7.84e-06	184	173	7	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	Control-Epithelial_cells-Airway_goblet\|Control / group, cell type (main and fine annotations)	CYP2C18 CYP3A5 ABCA13 MUC16 ATP10B CAPN8 CATSPERB	7.84e-06	184	173	7	d92a71441e4e19f8c301999d8186f8e48e3cd162
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	MON2 A2M TTC39B MMS22L VPS13C URB1 TMEM131L	8.13e-06	185	173	7	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_OPALIN\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 ATP10B NEK3 PLEKHG3 FAM124A MUSK PLXNB3	8.13e-06	185	173	7	1d731d69d8db8aef4a11439b8abd1030c7e6ac4c
ToppCell	Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 ATP10B NEK3 PLEKHG3 FAM124A MUSK PLXNB3	8.13e-06	185	173	7	b8d02c9426740ffcb69d2e6f95473b388149d297
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ABCA13 DOCK9 ATP10B DNAH14 CAPN8 CATSPERB GPC5	8.42e-06	186	173	7	acfa68a2afb7d2b51c9b469a1965fe5cc5d5e64e
ToppCell	Primary_Motor_Cortex_(M1)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 ATP10B NEK3 PLEKHG3 FAM124A MUSK PLXNB3	9.02e-06	188	173	7	14072d0b82df55711d5356b2209f4f0bdd90dc27
ToppCell	Epithelial-Epithelial-D_(Ciliated)\|Epithelial / shred on cell class and cell subclass (v4)	SYNE1 CEP290 CYP2S1 CFAP54 CCDC180 CFAP69 HYDIN	9.02e-06	188	173	7	8f30535a32968a81a304315a49c0d90a77d36948
ToppCell	Primary_Motor_Cortex_(M1)-Non-neuronal-Macroglial-Oligo\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH3TC2 ATP10B NEK3 PLEKHG3 FAM124A MUSK PLXNB3	9.34e-06	189	173	7	70eea8c94fa56bb15bee8065de47acea156794e9
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CACNA1D MYO10 ADGRB3 ABCA6 CHEK2 PLXNA4 ARHGAP20	9.34e-06	189	173	7	2a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCell	Control-Fibroblasts\|Control / group, cell type (main and fine annotations)	A2M CACNA1D ADGRB3 THBS2 DST ABCA6 MUSK	9.67e-06	190	173	7	3a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell	Severe-B_intermediate-1\|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)	RIPOR2 ERBIN PCNX2 TMEM266 TMEM131L CFAP69	9.96e-06	126	173	6	42a0bdbe18ef85146cac4e86b2b27d0b3b20d8a2
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_secretory_(0)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ABCC3 NEK10 ADGRV1 FRY CFAP54 GPC5 SLC44A3	1.00e-05	191	173	7	60ff989fe99d243a3d52955223680cdd1f1917a4
ToppCell	CD8+_Memory_T_cell-CV-7\|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster	MON2 A2M MMS22L VPS13C ARFGEF2 URB1 TMEM131L	1.00e-05	191	173	7	9454f642c3621370fa23640b631301346b300950
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MROH9 SH3TC2 ATP10B THBS2 PLEKHG3 MUSK PLXNB3	1.00e-05	191	173	7	2110a1dd10730ad7ee7a265fb1716ab3ddafcf4a
ToppCell	nucseq-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MROH9 ABCA13 NEK10 MUC16 CFAP54 CFAP69 HYDIN	1.00e-05	191	173	7	e417bf491f8b8d7838a61f7f4f6b1740ba97aa3f
ToppCell	nucseq-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MROH9 ABCA13 NEK10 MUC16 CFAP54 CFAP69 HYDIN	1.00e-05	191	173	7	9d31c8424d35bdc0c27188b68bfd0f731af3600b
ToppCell	nucseq-Epithelial-Epithelial_Airway\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MROH9 ABCA13 NEK10 MUC16 CFAP54 CFAP69 HYDIN	1.00e-05	191	173	7	1c528f72c9ef3ef3a850b05e4a9715190832270c
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CACNA1D FRMPD4 ADGRB3 ABCA6 CHEK2 PLXNA4 ARHGAP20	1.03e-05	192	173	7	6f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 ARHGEF17 KCNT2 NALCN KCNMA1 TMEM131L SNX31	1.03e-05	192	173	7	24e2f15f5767a97eb3b389922bcfd7b13805e1ce
ToppCell	COPD-Epithelial-Ciliated\|World / Disease state, Lineage and Cell class	MROH9 ABCA13 NEK10 MUC16 CFAP54 CFAP69 HYDIN	1.03e-05	192	173	7	eab1105cd1a98cfcd3d74dc5c9b89e1799bba59e
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	A2M CACNA1D MYO10 ADGRB3 DST ABCA6 MUSK	1.07e-05	193	173	7	99525545552b371c86b18b6ea6f4897dc6e9a9ec
ToppCell	COVID-19-Fibroblasts-Other_FB\|COVID-19 / group, cell type (main and fine annotations)	A2M CACNA1D THBS2 DST KCNT2 NALCN ABCA6	1.07e-05	193	173	7	e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCell	Mesenchymal-matrix_fibroblast_1_cell\|World / Lineage, Cell type, age group and donor	A2M CACNA1D MYO10 ADGRB3 DST ABCA6 ARHGAP20	1.07e-05	193	173	7	acad568621ed677031797b8c2e34dafea798d681
ToppCell	RV-09._Endothelium_I\|World / Chamber and Cluster_Paper	A2M SYNE1 DOCK9 ADGRG1 ABCB1 MMRN1 KCNB1	1.07e-05	193	173	7	e3fa47e2c7cd8a5b69186711c57751f2296de8ae
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	A2M CACNA1D MYO10 ADGRB3 DST ABCA6 MUSK	1.11e-05	194	173	7	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	CACNA1D MYO10 ADGRB3 DST ABCA6 ARHGAP20 PCCA	1.11e-05	194	173	7	b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	A2M FRY THBS2 KCNT2 NALCN KCNMA1 TMEM131L	1.11e-05	194	173	7	ebb038f94f49f5c655578d1b018676e10c6b7e3c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Macrophage_Dendritic-M2_Macrophage\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CCDC141 CEP170 GNA13 TLR2 KCNMA1 CMKLR1 NCKAP1L	1.11e-05	194	173	7	45708cb2cafde10bf4e4798b81d47c3b1f6aaa14
ToppCell	COVID-19-Epithelial-Ciliated_cells\|COVID-19 / Condition, Lineage and Cell class	ABCA13 NEK10 MUC16 CFAP54 CCDC180 CFAP69 HYDIN	1.11e-05	194	173	7	43be5fbd51dd58839cb03ca3ddd05a458e1ddb74
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 ATP10B KIF9 CCDC180 CFAP69 HYDIN	1.14e-05	195	173	7	d211a836cf711fdb91b10d512f09d462be937cc5
ToppCell	367C-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	A2M SYNE1 P2RY13 CCDC141 ABCA6 CMKLR1 DNM1	1.14e-05	195	173	7	4008fa86b5166087a4b20f89ae07e1dfc87c855d
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	CACNA1D MYO10 ADGRB3 DST ABCA6 ARHGAP20 PCCA	1.14e-05	195	173	7	0e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Macrophage_Dendritic\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CCDC141 CEP170 GNA13 TLR2 KCNMA1 CMKLR1 NCKAP1L	1.14e-05	195	173	7	247803cf58c6d9c561a52aa34e581188ddad197e
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	A2M CACNA1D MYO10 ADGRB3 DST ABCA6 PLXNA4	1.14e-05	195	173	7	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 MUC16 KIF9 CCDC180 CFAP69 HYDIN	1.14e-05	195	173	7	79dc031258579ea328181dda33710dd897f1064a
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c11-GNLY\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M SYNE1 ADGRG1 MTERF2 PLEKHG3 GNAO1 CMKLR1	1.18e-05	196	173	7	60f5deb97f3d6f8422bb5849778205a7022002ae
ToppCell	nucseq-Mesenchymal-Fibroblastic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	A2M CACNA1D ADGRB3 THBS2 DST ABCA6 MUSK	1.18e-05	196	173	7	7d8505dac15fa59935ccf592afc54b04c4c6554f
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	MYO10 SYNE1 DST ABCA6 LRRC7 ARHGAP20 CFAP69	1.22e-05	197	173	7	fdb92985f7df0c280b87d3e43c2394e70786a2c7
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	MROH9 CACNA1D MYO10 ADGRB3 DST ABCA6 ARHGAP20	1.22e-05	197	173	7	31a1852911bda38543916585fda34255fd62a134
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 SYNE1 MUC16 CCDC180 CFAP69 HYDIN	1.22e-05	197	173	7	91637bdeab85024b5a02d1066f76cb803a2d6420
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 SYNE1 MUC16 CCDC180 CFAP69 HYDIN	1.22e-05	197	173	7	22c87dd15dc57bd0aa98a204c9fc9b3b9b573b45
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 SYNE1 MUC16 CCDC180 CFAP69 HYDIN	1.22e-05	197	173	7	3bbf068d2ad8196fbc85d3f311a7c54c9aece856
ToppCell	control-Epithelial-Ciliated\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	NEK10 SYNE1 KIF9 CFAP54 CCDC180 CFAP69 HYDIN	1.22e-05	197	173	7	e453d085182364ca347cbcc9dc995c62c3353016
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Myeloid-Macrophages\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M P2RY13 CEP170 PLXNC1 TLR2 KCNMA1 CMKLR1	1.22e-05	197	173	7	e698a0bbb20bd4868ff4348f2ac9f609942b55fa
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	A2M CACNA1D THBS2 KCNT2 ABCA6 ABCC12 DNM1	1.22e-05	197	173	7	44673c38384453207871d3fd8e8ba9093cc06bc5
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ABCA13 NEK10 SYNE1 MUC16 CCDC180 CFAP69 HYDIN	1.22e-05	197	173	7	87db09f341e2b20eb6e1c3e917cb5c960387b3e9
ToppCell	Control-Myeloid-DC2\|Myeloid / Condition, Lineage and Cell class	A2M GPR18 P2RY13 CYP2S1 FCER1A PLXNC1 GNAO1	1.22e-05	197	173	7	e0ee15188ff0d9df3c3b5ea523553ce18d223c33
ToppCell	Transverse-(5)_Dendritic_cell-(53)_Lymphoid_DC\|Transverse / shred on region, Cell_type, and subtype	ABCC3 SCN11A CYP2S1 ABCA6 PLEKHG3 KCNMA1 DNM1	1.22e-05	197	173	7	15b87fd3906d7388c271d30d0c64b1bcc490801c
ToppCell	control-Epithelial-Ciliated\|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	NEK10 SYNE1 KIF9 CFAP54 CCDC180 CFAP69 HYDIN	1.22e-05	197	173	7	d4e963c1f82996371bf3d63578ee9fce8e00c5a8
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	A2M ADGRB3 THBS2 DST KCNT2 NALCN ABCA6	1.22e-05	197	173	7	6d0d68d460243a0259ada93ebda40fa7b3088eeb
ToppCell	Transverse-Dendritic_cell-Lymphoid_DC\|Transverse / Region, Cell class and subclass	ABCC3 SCN11A CYP2S1 ABCA6 PLEKHG3 KCNMA1 DNM1	1.22e-05	197	173	7	a58af0ea82f76f2a7abac1f62629ff20d552fc63
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	A2M CACNA1D ADGRB3 THBS2 DST ABCA6 ARHGAP20	1.26e-05	198	173	7	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	distal-Hematologic-Myeloid_Dendritic_Type_2-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	P2RY13 CYP2S1 FCER1A PLXNC1 LRRC7 ECEL1 GNAO1	1.26e-05	198	173	7	984b3753fabd5553f6f364f90a422b035e421535
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FRMPD4 SYNE1 ADGRB3 FRY KCNMA1 DNM1 UNC79	1.26e-05	198	173	7	8ab40fae14fe02e39bc8c8da187a5cd60c787643
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CACNA1D FRMPD4 SYNE1 FRY KCNMA1 DNM1 UNC79	1.26e-05	198	173	7	4ca5ff320905ab4ff60ed90a5522227c782142a6
ToppCell	COVID-19-lung-Fibroblast\|lung / Disease (COVID-19 only), tissue and cell type	A2M CACNA1D ADGRB3 THBS2 DST ABCA6 PLXNA4	1.26e-05	198	173	7	df3de77216f5c5d6141ec44d01c56b942f611838
ToppCell	nucseq-Mesenchymal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	A2M CACNA1D ADGRB3 THBS2 DST ABCA6 MUSK	1.26e-05	198	173	7	8f52243ca8b9ba68a75ae411506a3a6de258eb97
ToppCell	Mesenchymal\|World / Lineage, Cell type, age group and donor	A2M CACNA1D ADGRB3 THBS2 DST KCNT2 ABCA6	1.31e-05	199	173	7	4bac110c2b3609f6ee5d0e3275da0824a6240270
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	CACNA1D MYO10 SYNE1 DST ABCA6 PLXNA4 ARHGAP20	1.31e-05	199	173	7	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MROH9 SYNE1 DOCK9 ATP10B LRRC7 UNC79 HYDIN	1.31e-05	199	173	7	19a97e27a4758e794ce7246d295e112b47931a48
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	MON2 CLASP1 ADGRB3 FAF1 KCNMA1 PCCA HERC4	1.31e-05	199	173	7	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CACNA1D SYNE1 DST ABCA6 CHEK2 PLXNA4 ARHGAP20	1.35e-05	200	173	7	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	Tracheal-NucSeq-Stromal-Chondrocytic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	A2M SYNE1 FRY CFAP54 KCNT2 GPC5 DNM1	1.35e-05	200	173	7	b5a54b9baf79aea01f76a161f0a39bbe87eb4945
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Dendritic_cell\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	P2RY13 CYP2S1 FCER1A PLXNC1 GNA13 GNAO1 NCKAP1L	1.35e-05	200	173	7	f19b729b03b5f225b9ed676f0ac31071a4354da3
ToppCell	Tracheal-NucSeq-Stromal-Chondrocytic-Chondrocyte\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	A2M SYNE1 FRY CFAP54 KCNT2 GPC5 DNM1	1.35e-05	200	173	7	f5bd0b30e478dac09f68c46b0781f5f2e7e3c693
Drug	7-benzyloxyquinoline	CYP2C8 CYP2C9 CYP3A5 ABCB1 ABCC2	1.84e-07	18	172	5	CID003035604
Drug	verapamil	CACNA1D ABCC3 CYP2C8 CYP2C9 CYP2C18 CYP3A5 ABCA13 ABCB1 ATP2C1 KCNT2 ART1 KCNB1 ABCA6 KCNMA1 ABCC12 ABCC2 MUSK	2.02e-07	490	172	17	CID000002520
Drug	D 617	CYP2C8 CYP2C9 CYP2C18 CYP3A5 ABCB1	2.48e-07	19	172	5	CID000093168
Drug	lovastatin acid	ABCC3 CYP2C8 CYP2C9 ABCB1 ABCC2	3.28e-07	20	172	5	CID000064727
Drug	hypaconitine	CYP2C8 CYP3A5 ABCB1 ABCC2	6.37e-07	10	172	4	ctd:C058309
Drug	Ticlopidine	ABCC3 CYP2C8 CYP2C9 CYP3A5 ABCC2	1.09e-06	25	172	5	ctd:D013988
Drug	DMEs	ABCC3 CYP2C8 CYP2C9 CYP2C18 CYP3A5 ABCB1 TLR2	1.10e-06	71	172	7	CID003038361
Drug	glibenclamide	CACNA1D ABCC3 CYP2C8 CYP2C9 CYP3A5 ABCA13 ABCB1 ART1 KCNB1 CLCNKA ABCA6 KCNMA1 ABCC12 ABCC2	1.33e-06	382	172	14	CID000003488
Drug	5-hydroxydiclofenac	CYP2C8 CYP2C9 CYP2C18 CYP3A5	1.48e-06	12	172	4	CID003052566
Drug	BP-9,10-oxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.64e-06	27	172	5	CID000037456
Drug	Brn 4136738	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.64e-06	27	172	5	CID000050331
Drug	C14845	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.64e-06	27	172	5	CID011954064
Drug	macitentan	ABCC3 ABCB1 ABCC2	1.69e-06	4	172	3	ctd:C533860
Drug	norverapamil	CYP2C8 CYP2C9 CYP2C18 CYP3A5 ABCB1	1.98e-06	28	172	5	CID000104972
Drug	9-OH-BaP-4,5-oxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.98e-06	28	172	5	CID000115064
Drug	19-hydroxytestosterone	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	2.84e-06	30	172	5	CID000150968
Drug	11-H-14,15-EETA	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	2.84e-06	30	172	5	CID011954058
Drug	Ro 31-8959	ABCC3 CYP2C8 CYP2C9 CYP3A5 ABCB1 CUL5 ABCC2	3.45e-06	84	172	7	CID000060787
Drug	chloroacetyl chloride	CYP2C8 CYP2C9 CYP2C18 CYP3A5 SYNE1 CYP2S1	3.63e-06	55	172	6	CID000006577
Drug	BP-7,8-oxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.96e-06	32	172	5	CID000037455
Drug	2'-(glutathion-S-yl)-deschlorodiclofenac	CYP2C8 CYP2C9 CYP2C18 CYP3A5	4.02e-06	15	172	4	ctd:C586542
Drug	12(13)-EpOME	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	5.41e-06	34	172	5	CID000001416
Drug	TCEO	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	5.41e-06	34	172	5	CID000028167
Drug	AC1O5XSP	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	5.41e-06	34	172	5	CID006442739
Drug	AC1L1CJI	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	6.27e-06	35	172	5	CID000001929
Drug	15-H-11,12-EETA	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	7.24e-06	36	172	5	CID011954042
Drug	AC1L3NGJ	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	7.24e-06	36	172	5	CID000092121
Drug	hydrocotarnine	CYP2C9 CYP3A5 ABCB1	8.33e-06	6	172	3	CID000003646
Drug	4',5-dihydroxydiclofenac	CYP2C8 CYP2C9 CYP2C18	8.33e-06	6	172	3	CID003052567
Drug	3'-hydroxydiclofenac	CYP2C8 CYP2C9 CYP2C18	8.33e-06	6	172	3	CID000112230
Drug	Azamulinum	CYP2C8 CYP2C9 CYP2C18 CYP3A5	8.86e-06	18	172	4	CID003086060
Drug	D 703	CYP2C8 CYP2C9 CYP2C18 ABCB1	8.86e-06	18	172	4	CID000054088
Drug	adefovir	ABCC3 CYP2C9 ABCB1 IFNE ABCC12 ABCC2	8.88e-06	64	172	6	CID000060172
Drug	11,14,15-THET	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.09e-05	39	172	5	CID006439531
Drug	nanofin	CYP2C8 CYP2C9 CYP3A5 ABCB1 ABCC2	1.09e-05	39	172	5	CID000068843
Drug	hydroxytolbutamide	CYP2C8 CYP2C9 CYP2C18 CYP3A5	1.12e-05	19	172	4	CID000003656
Drug	(Z) Fluvoxamine	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 ABCB1	1.38e-05	69	172	6	CID000003404
Drug	3C etc	CYP2C8 CYP2C9 CYP2C18 CYP3A5	1.39e-05	20	172	4	CID000164045
Drug	3-MeO	CYP2C9 CYP3A5 SYNE1	1.45e-05	7	172	3	CID009574960
Drug	16-O-demethylaconitine	CYP2C8 CYP2C9 CYP3A5	1.45e-05	7	172	3	ctd:C486136
Drug	4-bromophenol	CYP2C8 CYP2C9 CYP2C18 CYP3A5 SYNE1 CYP2S1	1.50e-05	70	172	6	CID000007808
Drug	11,12,15-trihydroxyeicosatrienoic acid	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	1.57e-05	42	172	5	CID006439610
Drug	L 654969	ABCC3 CYP2C8 CYP2C9 CYP3A5 ABCB1	1.57e-05	42	172	5	CID000005218
Drug	chloral	CYP2C8 CYP2C9 CYP2C18 CYP3A5 AASDH CYP2S1	1.91e-05	73	172	6	CID000006407
Drug	Deltaline [6836-11-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	A2M ABCC3 SCN11A CYP2C9 CYP2C18 CYP3A5 SYNE1 PCNX2 HERC4	2.06e-05	198	172	9	3831_UP
Drug	naphthalene-1,2-dihydrodiol	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	2.22e-05	45	172	5	CID000000362
Drug	13-hydroxyeicosatetraenoic acid	CYP2C8 CYP2C9 CYP3A5	2.31e-05	8	172	3	CID006439499
Drug	11-HODE	CYP2C8 CYP2C9 CYP3A5	2.31e-05	8	172	3	CID006438497
Drug	calcein AM	ABCC3 ABCB1 ABCC2	2.31e-05	8	172	3	ctd:C085925
Drug	nicotine glucuronide	ABCC3 ABCB1 ABCC2	2.31e-05	8	172	3	CID003035848
Drug	T beta-MC	ABCC3 ABCB1 ABCC2	2.31e-05	8	172	3	CID000168408
Drug	Nifedipine	CACNA1D ABCC3 CYP2C8 CYP2C9 ABCB1 CSE1L ABCC2	2.31e-05	112	172	7	ctd:D009543
Drug	3-hydroxymethylantipyrine	CYP2C8 CYP2C9 CYP2C18 CYP3A5	2.49e-05	23	172	4	CID000123963
Drug	C14802	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	2.75e-05	47	172	5	CID011954053
Drug	halothane	CACNA1D CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 PGD ATP2C1 KCNB1 KCNMA1 MUSK	2.84e-05	314	172	11	CID000003562
Drug	nitro-L	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.06e-05	48	172	5	CID000006849
Drug	C14800	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.06e-05	48	172	5	CID011954051
Drug	19-HETE	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.38e-05	49	172	5	CID006439528
Drug	bromobenzene-3,4-oxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.38e-05	49	172	5	CID000108121
Drug	ND-Z	CYP2C8 CYP2C9 CYP3A5	3.44e-05	9	172	3	CID000162892
Drug	Acenocoumarol	CYP2C9 CYP2C18 ABCB1	3.44e-05	9	172	3	ctd:D000074
Drug	AC1MHWVC	CYP2C9 CYP3A5 SYNE1	3.44e-05	9	172	3	CID003034089
Drug	p-hydroxyphenobarbital	ABCC3 CYP3A5 ABCC2	3.44e-05	9	172	3	CID000009785
Drug	Aconitine	CYP2C8 CYP2C9 CYP3A5 ABCB1	3.51e-05	25	172	4	ctd:D000157
Drug	bromobenzene-2,3-oxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.74e-05	50	172	5	CID003036760
Drug	6-hydroxymelatonin	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.74e-05	50	172	5	CID000001864
Drug	1,1-dichloroethylene epoxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	3.74e-05	50	172	5	CID000119521
Drug	fluo-3	CACNA1D ABCC3 ABCB1 ATP2C1 ART1 KCNMA1 ABCC2	4.01e-05	122	172	7	CID000104978
Drug	naphthalene epoxide	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	4.12e-05	51	172	5	CID000108063
Drug	1,4-naphthoquinone	CYP2C8 CYP2C9 CYP2C18 CYP3A5	4.13e-05	26	172	4	ctd:C035342
Drug	diosmetin	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 ABCC2	4.55e-05	85	172	6	CID005281612
Drug	pseudohypericin	CYP2C9 CYP3A5 ABCB1 ARSL	4.82e-05	27	172	4	CID005281751
Drug	norketobemidone	CYP2C8 CYP2C9 ABCB1	4.89e-05	10	172	3	CID000161154
Drug	AC1L2XOG	CYP2C9 CYP3A5 ABCB1	4.89e-05	10	172	3	CID000130599
Drug	9-hydroxybenzo(a)pyrene	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	4.97e-05	53	172	5	CID000028598
Drug	Gsts	ABCC3 SCN11A CYP2C9 CYP2C18 CYP3A5 ABCB1 ABCC12 ABCC2	5.29e-05	173	172	8	CID000128079
Drug	triazolam	CYP2C8 CYP2C9 CYP2C18 CYP3A5 ABCB1	5.44e-05	54	172	5	CID000005556
Drug	dichloroacetaldehyde	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	5.44e-05	54	172	5	CID000006576
Drug	erucin	CYP3A5 ABCB1 ABCC2 DNM1	5.59e-05	28	172	4	CID000078160
Drug	enkephalin-Leu, Ala(2)-melphalan methyl ester-	ABCB1 ABCC2	5.67e-05	2	172	2	ctd:C040240
Drug	Thcd	CYP3A5 PGD	5.67e-05	2	172	2	CID006439451
Drug	5(6)-carboxy-2',7'-dichlorofluorescein	ABCC3 ABCC2	5.67e-05	2	172	2	ctd:C053897
Drug	NSC73306	SLC31A1 ABCB1	5.67e-05	2	172	2	ctd:C511311
Drug	benzoylmesaconine	ABCB1 ABCC2	5.67e-05	2	172	2	ctd:C085283
Drug	benzoylaconine	ABCB1 ABCC2	5.67e-05	2	172	2	ctd:C047307
Drug	E3040 glucuronide	ABCC3 ABCC2	5.67e-05	2	172	2	CID000443294
Drug	14(15)-EpETrE	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 KCNMA1	5.89e-05	89	172	6	CID000001431
Drug	(hydrochloride)	CYP2C8 CYP2C9 CYP2C18 CYP3A5	6.45e-05	29	172	4	CID000004923
Drug	3 alpha,6 alpha-dihydroxy-5 beta-cholanoic acid	ABCC3 SYNE1 ABCB1 ABCC2	6.45e-05	29	172	4	CID000006747
Drug	parathion	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 ABCB1	6.68e-05	91	172	6	CID000000991
Drug	Haloperidol metabolite I	CYP2C8 CYP2C9 CYP3A5	6.69e-05	11	172	3	CID000038282
Drug	Sulfinpyrazone	CYP2C8 CYP2C9 ABCC2	6.69e-05	11	172	3	ctd:D013442
Drug	Troleandomycin	CYP3A5 ABCB1 ABCC2	6.69e-05	11	172	3	ctd:D014217
Drug	Metronidazole	ABCC3 CYP2C9 ABCC2	6.69e-05	11	172	3	ctd:D008795
Drug	Ticalopride	CYP2C8 CYP3A5 ABCB1	6.69e-05	11	172	3	CID000216236
Drug	1,2-dihydroxynaphthalene	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	7.07e-05	57	172	5	CID000011318
Drug	bosentan	ABCC3 CYP2C9 ABCB1 ABCC2	7.39e-05	30	172	4	ctd:C086232
Drug	tienilic acid	ABCC3 CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1	7.54e-05	93	172	6	CID000038409
Drug	AC1L1BEQ	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 KCNMA1	7.54e-05	93	172	6	CID000001407
Drug	lansoprazole	CYP2C8 CYP2C9 CYP2C18 CYP3A5 CYP2S1 ABCB1	7.54e-05	93	172	6	CID000003883
Disease	ecosanoids measurement	ABCC3 CYP2C8 CYP2C9 CYP2C18 CYP3A5 ABCC2 MUSK	2.44e-08	55	165	7	EFO_0020044
Disease	Drug toxicity	CYP2C8 CYP2C9 ABCB1 TLR2 ABCC12 ABCC2	7.91e-06	84	165	6	C0013221
Disease	Adverse reaction to drug	CYP2C8 CYP2C9 ABCB1 TLR2 ABCC12 ABCC2	7.91e-06	84	165	6	C0041755
Disease	Colorectal Neoplasms	ABCC3 DONSON ABCA13 SYNE1 ABCB1 ABCA6 TLR2 CHEK2 ABCC2	2.78e-05	277	165	9	C0009404
Disease	cerebrospinal fluid clusterin measurement	ABCA13 DST SNX31 FAM124A	4.31e-05	35	165	4	EFO_0007657
Disease	phoneme awareness	ARFGEF2 CSE1L KCNB1	5.97e-05	14	165	3	EFO_0021812
Disease	progressive familial intrahepatic cholestasis (implicated_via_orthology)	ATP10B ATP10D	9.29e-05	3	165	2	DOID:0070221 (implicated_via_orthology)
Disease	X-21258 measurement	CYP2C9 CYP2C18	9.29e-05	3	165	2	EFO_0800802
Disease	keratoconjunctivitis (is_marker_for)	MUC16 TLR2	9.29e-05	3	165	2	DOID:9368 (is_marker_for)
Disease	end stage renal disease (biomarker_via_orthology)	ABCC3 CYP2C18 CYP3A5 ABCB1	1.39e-04	47	165	4	DOID:783 (biomarker_via_orthology)
Disease	metabolonic lactone sulfate measurement	CYP2C9 CYP2C18 CYP3A5	1.56e-04	19	165	3	EFO_0800659
Disease	cholestasis (biomarker_via_orthology)	ABCC3 CYP3A5 ABCB1 ABCC2	1.64e-04	49	165	4	DOID:13580 (biomarker_via_orthology)
Disease	chronic myeloid leukemia (is_implicated_in)	CYP3A5 ABCB1 ABCC2	2.12e-04	21	165	3	DOID:8552 (is_implicated_in)
Disease	nervous system disorder	CYP2C8 CYP2C9 ABCB1 ABCC2	2.23e-04	53	165	4	C0027765
Disease	Intellectual Disability	FRMPD4 SLC31A1 KDM5A SYNE1 TMX2 FRY VPS53 STAG2 DYNC1H1 ZMYM6	2.23e-04	447	165	10	C3714756
Disease	essential hypertension, age at diagnosis	CHEK2 GNAO1 TBX20 UNC79	2.76e-04	56	165	4	EFO_0004918, MONDO_0001134
Disease	serum metabolite measurement	MROH9 NRBP1 SH3TC2 CYP2C8 CYP2C9 CYP2C18 CYP3A5 ATP10D KCNT2 DNAH17 ABCC2 ARHGAP20 CCDC180 MUSK RIC1	2.87e-04	945	165	15	EFO_0005653
Disease	hereditary sensory neuropathy (implicated_via_orthology)	SCN11A DST	3.07e-04	5	165	2	DOID:0050548 (implicated_via_orthology)
Disease	EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1	GNAO1 DNM1	4.59e-04	6	165	2	C3463992
Disease	3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-CMPFP) measurement	CYP2C8 ABCC2	4.59e-04	6	165	2	EFO_0800566
Disease	response to ranibizumab	PLXNC1 KCNMA1	4.59e-04	6	165	2	EFO_0008348
Disease	phosphatidylcholine 38:4 measurement	FRMPD4 ADGRV1 MUSK	5.08e-04	28	165	3	EFO_0010386
Disease	peak expiratory flow	UTP6 DOCK9 ARHGEF17 PGD FAF1 FRY DST GNAO1 TBX20 PCCA	5.22e-04	498	165	10	EFO_0009718
Disease	Microcephaly	DONSON TMX2 STAG2 DYNC1H1	5.49e-04	67	165	4	C0025958
Disease	glycine conjugate of C10H14O2 (1) measurement	CYP2C9 CYP2C18	6.41e-04	7	165	2	EFO_0800655
Disease	bilirubin metabolic disorder (biomarker_via_orthology)	ABCC3 ABCC2	6.41e-04	7	165	2	DOID:2741 (biomarker_via_orthology)
Disease	X-linked infantile spasms	GNAO1 DNM1	8.51e-04	8	165	2	C4552072
Disease	allergic rhinitis (is_implicated_in)	ABCB1 TLR2	8.51e-04	8	165	2	DOID:4481 (is_implicated_in)
Disease	female breast cancer (is_implicated_in)	PALB2 CHEK2	8.51e-04	8	165	2	DOID:0050671 (is_implicated_in)
Disease	Drug Allergy	CYP2C9 FCER1A ABCC2	9.85e-04	35	165	3	C0013182
Disease	Malignant neoplasm of breast	SYNE1 ARFGEF2 HELQ SP110 PALB2 ABCB1 CUL5 TAS2R13 TXNDC15 KCNT2 EIF4A2 CHEK2 UTP20 LRRC7 DOP1A	1.07e-03	1074	165	15	C0006142
Disease	Duchenne muscular dystrophy (implicated_via_orthology)	CACNA1D CAPN8 KCNMA1	1.07e-03	36	165	3	DOID:11723 (implicated_via_orthology)
Disease	Distal arthrogryposis	NALCN ECEL1	1.09e-03	9	165	2	cv:C0265213
Disease	cystic fibrosis (implicated_via_orthology)	ABCB1 ABCC12	1.09e-03	9	165	2	DOID:1485 (implicated_via_orthology)
Disease	epilepsy (is_implicated_in)	ABCB1 KCNB1	1.09e-03	9	165	2	DOID:1826 (is_implicated_in)
Disease	cleft lip	SYNE1 ADGRB3 MUC16 FRY DST GPC5 TBX20	1.13e-03	284	165	7	EFO_0003959
Disease	platelet component distribution width	SH3TC2 SCN11A SYNE1 DOCK9 KIF9 PLEKHG3 CHEK2 TMEM131L CATSPERB DNM1 MUSK XPO7	1.16e-03	755	165	12	EFO_0007984
Disease	metabolite measurement	MROH9 ABCC3 CYP2C8 CYP2C9 CYP3A5 ATP10D TUBGCP6 ABCC2 TBX20 MUSK	1.27e-03	560	165	10	EFO_0004725
Disease	cup-to-disc ratio measurement, optic cup area measurement, optic disc area measurement	PLEKHG3 FAM124A	1.36e-03	10	165	2	EFO_0006937, EFO_0006939, EFO_0006940
Disease	2-ketocaprylate measurement	PCNX4 TMEM266	1.36e-03	10	165	2	EFO_0800110
Disease	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO (finding)	SP110 TLR2	1.36e-03	10	165	2	C1834752
Disease	Mycobacterium tuberculosis, susceptibility to	SP110 TLR2	1.36e-03	10	165	2	cv:C1834752
Disease	MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO	SP110 TLR2	1.36e-03	10	165	2	607948
Disease	dry eye syndrome (is_marker_for)	MUC16 TLR2	1.36e-03	10	165	2	DOID:10140 (is_marker_for)
Disease	left ventricular ejection fraction measurement	CCDC141 CLCNKA GNAO1	1.46e-03	40	165	3	EFO_0008373
Disease	cortical thickness	MON2 A2M RIPOR2 DOCK9 ARFGEF2 PLXND1 ADGRV1 FAF1 ZBTB34 PLXNC1 GNA13 UTP4 SNX31 PCCA MUSK	1.52e-03	1113	165	15	EFO_0004840
Disease	S-6-hydroxywarfarin to S-warfarin ratio measurement	CYP2C8 CYP2C9 CYP2C18 HERC4	1.53e-03	88	165	4	EFO_0803332
Disease	forced expiratory volume	CACNA1D SYNE1 DOCK9 ARFGEF2 ARHGEF17 FAF1 CSE1L DST PLXNA4 KCNMA1 GPC5 GNAO1	1.68e-03	789	165	12	EFO_0004314
Disease	epilepsy (implicated_via_orthology)	SCN11A ABCB1 KCNT2 KCNMA1 DYNC1H1	2.28e-03	163	165	5	DOID:1826 (implicated_via_orthology)
Disease	Neuroblastoma	ABCB1 CHEK2 CHD6	2.32e-03	47	165	3	C0027819
Disease	glycochenodeoxycholate glucuronide (1) measurement	ABCC3 ABCC2	2.33e-03	13	165	2	EFO_0800474
Disease	level of Sphingomyelin (d34:2) in blood serum	MUSK RIC1	2.33e-03	13	165	2	OBA_2045174
Disease	X-24588 measurement	ABCC3 ABCC2	2.33e-03	13	165	2	EFO_0800898
Disease	developmental and epileptic encephalopathy (implicated_via_orthology)	GNAO1 DNM1	2.33e-03	13	165	2	DOID:0112202 (implicated_via_orthology)
Disease	developmental disorder of mental health (implicated_via_orthology)	PLXND1 PLXNB3 NCKAP1L	2.62e-03	49	165	3	DOID:0060037 (implicated_via_orthology)
Disease	urate measurement, bone density	CYP2C8 SYNE1 ADGRB3 ERBIN DNAH14 SLC26A8 PLXNC1 PLXNA4 KCNMA1 GPC5	2.63e-03	619	165	10	EFO_0003923, EFO_0004531
Disease	level of Phosphatidylethanolamine (18:2_0:0) in blood serum	NRBP1 MUSK	2.71e-03	14	165	2	OBA_2045143
Disease	Hereditary Breast and Ovarian Cancer Syndrome	PALB2 CHEK2	2.71e-03	14	165	2	C0677776
Disease	lung carcinoma, estrogen-receptor negative breast cancer, ovarian endometrioid carcinoma, colorectal cancer, prostate carcinoma, ovarian serous carcinoma, breast carcinoma, ovarian carcinoma, lung adenocarcinoma, squamous cell lung carcinoma	NEK10 FRY GNAO1	3.10e-03	52	165	3	EFO_0000305, EFO_0000571, EFO_0000708, EFO_0001071, EFO_0001075, EFO_0001663, EFO_1000650, EFO_1001515, EFO_1001516, MONDO_0005575
Disease	Down syndrome (implicated_via_orthology)	SYNJ1 DOP1A	3.11e-03	15	165	2	DOID:14250 (implicated_via_orthology)
Disease	16a-hydroxy DHEA 3-sulfate measurement	CYP2C8 CYP2C9	3.11e-03	15	165	2	EFO_0800301
Disease	glucose-dependent insulinotropic peptide measurement	RIPOR2 CCDC141 FAM124A	3.28e-03	53	165	3	EFO_0008464
Disease	Epilepsy	ABCB1 KCNT2 GNAO1 DNM1	3.33e-03	109	165	4	C0014544
Disease	mental or behavioural disorder	TTC39B COL28A1 VPS13C KCNT2 NALCN	3.41e-03	179	165	5	EFO_0000677
Disease	response to antineoplastic agent, response to antimicrotubule agent	TMEM131L GPC5	3.54e-03	16	165	2	EFO_0005260, GO_0097327
Disease	Early infantile epileptic encephalopathy with suppression bursts	GNAO1 DNM1	3.54e-03	16	165	2	C0393706
Disease	andro steroid monosulfate C19H28O6S (1) measurement	CYP2C8 CYP2C9	3.54e-03	16	165	2	EFO_0800305
Disease	acute lymphoblastic leukemia (is_implicated_in)	CYP3A5 ABCB1 ABCC2	3.64e-03	55	165	3	DOID:9952 (is_implicated_in)
Disease	heart failure	CCDC141 FAF1 CLCNKA GNAO1 HEATR5B	3.92e-03	185	165	5	EFO_0003144
Disease	X-21441 measurement	ABCC3 ABCC2	4.00e-03	17	165	2	EFO_0800814
Disease	level of Phosphatidylcholine (14:0_18:2) in blood serum	NRBP1 MUSK	4.00e-03	17	165	2	OBA_2045063
Disease	phospholipids in small LDL measurement	ABCA6 GNAO1 KPNB1	4.44e-03	59	165	3	EFO_0022297
Disease	Meckel syndrome type 1	CEP290 TXNDC15	4.48e-03	18	165	2	C3714506
Disease	phosphatidylcholine 36:4 measurement	RIPOR2 MUSK	4.48e-03	18	165	2	EFO_0010382
Disease	caudal middle frontal gyrus volume measurement	FRY PCNX4	4.48e-03	18	165	2	EFO_0010290
Disease	sphingomyelin measurement	NRBP1 TTC39B ABCA6 MUSK DYNC1H1 KPNB1	4.87e-03	278	165	6	EFO_0010118
Disease	diet measurement, HOMA-B	PCNX2 PLXNA4	4.99e-03	19	165	2	EFO_0004469, EFO_0008111
Disease	Hereditary Non-Polyposis Colon Cancer Type 2	PALB2 CHEK2	4.99e-03	19	165	2	C1333991
Disease	Colorectal cancer, hereditary nonpolyposis, type 1	PALB2 CHEK2	4.99e-03	19	165	2	C2936783
Disease	APOE carrier status, dementia	RIPOR2 OR4D1 MUSK	5.10e-03	62	165	3	EFO_0007659, MONDO_0001627
Disease	omega-6 polyunsaturated fatty acid measurement	TTC39B ABCA6 GNAO1 MUSK KPNB1	5.11e-03	197	165	5	EFO_0005680
Disease	uterine fibroid	NEK10 SYNE1 ERBIN COG6 CHEK2	5.33e-03	199	165	5	EFO_0000731
Disease	end stage renal disease (implicated_via_orthology)	ABCB1 ABCC2	5.53e-03	20	165	2	DOID:783 (implicated_via_orthology)
Disease	Adenocarcinoma of prostate	PALB2 CHEK2	5.53e-03	20	165	2	C0007112
Disease	polymyositis	UBE3B GNAO1	5.53e-03	20	165	2	EFO_0003063

Protein segments in the cluster

Peptide	Gene	Start	Entry
LLLSSVFQFSKKIRQ	CEP170	1416	Q5SW79
AVSLLKTFQNTVELI	ERBIN	1391	Q96RT1
GLFISTQQQVTFLLK	FCER1A	221	P12319
VFSTLTLLQDSKLFE	CFAP54	2326	Q96N23
KLNFLFQVLALVALT	ARSL	196	P51690
VEQLLTLFNRFSKLV	CUL5	341	Q93034
FLITSILDNKNALAI	CATSPERB	666	Q9H7T0
TDKRSILFQILFAVF	ADGRB3	1121	O60242
LNVSLFPKDTINFLS	CYP3A5	236	P20815
LKAVNVLNLTRLTFF	GPR18	181	Q14330
VQFDILTVKENLSLF	ABCA6	566	Q8N139
IKNQVFLSLGSNFTL	ADGRV1	4836	Q8WXG9
VFELSLAIFLTLLSN	ARFGEF2	451	Q9Y6D5
FLFLTTILQNFNLKS	CYP2C8	446	P10632
FQFLNNLLKSPTASI	ABCA13	691	Q86UQ4
FLIEITANILKFQDT	PGD	231	P52209
AELIKTANLLFNSFE	DOP1A	416	Q5JWR5
KTVVNAASELSNFLL	AASDH	36	Q4L235
ITANALKILLNEAFS	CAPN8	551	A6NHC0
ITNLATFTEKFLLQL	CCDC180	1551	Q9P1Z9
LSLSRNKVFVFFDLT	CHEK2	191	O96017
QTLSFQEIALLKAVL	DHX29	1206	Q7Z478
KVFQTESLSILDLLF	ATP2C1	866	P98194
SIELVKLGQVFFLSN	ATP10B	386	O94823
FALQESLQKQFLELT	ATP10D	1006	Q9P241
LIYLDKVSNQTLSLF	A2M	1416	P01023
KVSNQTLSLFFTVLQ	A2M	1421	P01023
VTKAQAETLLLSVFQ	RIC1	581	Q4ADV7
EKAFVSVSLFNILRL	ABCC3	566	O15438
ATNERLFVLTTKNLF	NUDCD1	561	Q96RS6
SLFSVFNNVILEESK	LRRC9	631	Q6ZRR7
ETKRQNSNLFSLLFL	ABCB1	746	P08183
ALLVQSFSKDVLVNI	ARHGEF17	1146	Q96PE2
LVEQVFLDKTLNASF	MUC16	14276	Q8WXI7
QFSEILQFLNILKTS	KCNMA1	281	Q12791
IFELLTLKRTFDATN	NEK9	241	Q8TD19
AVLLLKSFQNTVDLV	LRRC7	1516	Q96NW7
QQFLQTSSSTLKFLI	GPC5	86	P78333
LTSAVNSLNFIIKEL	MMRN1	681	Q13201
LTRLLFNLSEVKSIF	MMS22L	856	Q6ZRQ5
SILAFILQLFKETNT	MMS22L	1091	Q6ZRQ5
FQQNLVSSALFSKVL	DST	1686	Q03001
NNTKEFIFSELLANL	DNM1	691	Q05193
ALLFVISLFLSNLDK	LMBRD1	316	Q9NUN5
FLAEKHLLLSNTFLQ	BAIAP2L2	186	Q6UXY1
AKAELFLFFTTILQA	CYP2S1	446	Q96SQ9
FSNLDVDIQFSLKRL	FAM124A	211	Q86V42
FLEFVSLLESINTSK	PCNX2	576	A6NKB5
QFISKLQFAVTVLLT	PCNX4	536	Q63HM2
NKVFLLSFIRTLESQ	PLXNA4	1361	Q9HCM2
TQLSNLLNSKLFLLT	PLXNB3	1371	Q9ULL4
LFASFLTIALQTKLV	PLXNC1	1086	O60486
SLFSSLLNNKHFLIV	PLXND1	1411	Q9Y4D7
FQEIFTALVKNRLIS	NEK10	106	Q6ZWH5
LQRNVISSSSFKLFL	GPS1	306	Q13098
KFLLASVLALQNSSF	DDIAS	6	Q8IXT1
FNSFLHTALKVLEIL	HERC4	586	Q5GLZ8
EITFKIFSQLDIRSL	FBXO48	41	Q5FWF7
LKFLSVISQQSLELS	MYO10	171	Q9HD67
SFVSILSSLNLKQVD	NCKAP1L	461	P55160
LQAFKTALENFSRAL	LRRC14B	496	A6NHZ5
FSLVLKFRSQLISQA	TUBGCP6	1741	Q96RT7
AQKAFTSITLFNILR	ABCC2	576	Q92887
FFLLILKRNSAFIQE	TEPSIN	86	Q96N21
DAKTIVNVQTLFRLF	KCNT2	816	Q6UVM3
TYINKSLSFLEQAII	KIF9	266	Q9HAQ2
FSNVSIILFLNKTDL	GNA13	281	Q14344
VSLAALKSFQEILQI	MON2	1161	Q7Z3U7
SKFIFLGLSQDLQTQ	OR2D3	26	Q8NGH3
EKNQLLAIASSLFVA	PCCA	521	P05165
LLQFESQLKIIESSF	MROH9	56	Q5TGP6
FLLRNKSVLDIVFSS	OR4D6	61	Q8NGJ1
FKNILNSIRFSIQLS	ECEL1	536	O95672
LTVEELKAFVQQLFS	KDM5A	821	P29375
SLKILNLSFNNLTAL	LRRC70	326	Q7Z2Q7
LNILKNADLSLAFQT	NEK3	416	P51956
FLLQVFTKSLFTEDT	HPDL	321	Q96IR7
EQGFTSFEILQLLSK	MTERF2	236	Q49AM1
RLTSLLEETLNKFNF	NRBP1	506	Q9UHY1
LSLFLIQLLISFSEN	PTTG1IP2	16	P0DTF9
LFFISLPNTILSNKE	P2RY13	171	Q9BPV8
LQNQLFIAKETTLFL	P2RY13	291	Q9BPV8
FIAKETTLFLAATNI	P2RY13	296	Q9BPV8
KQLLSFLSITDFQLP	PALB2	601	Q86YC2
KAQNFTSILIANLSL	NPY6R	66	Q99463
ALKALSTFFVENSLR	COG6	56	Q9Y2V7
QLALTANLNDTLTFK	HYDIN	866	Q4G0P3
AVQLNIFTAVLSALK	HEATR5B	821	Q9P2D3
TIFLTESNKSVLQFQ	KCNB1	276	Q14721
SNKISNFLLFISVVS	CASD1	636	Q96PB1
SLALLNKSQQLTDFI	CCDC141	181	Q6ZP82
IKLAALQFSSSVQID	COL28A1	91	Q2UY09
DTLSLFTLAFKNQLL	DOCK9	1406	Q9BZ29
NIFQGLLFSTAEVLK	DNAH17	2661	Q9UFH2
DKLIFLAQVTFQVLS	DNAH17	3726	Q9UFH2
GKTIQSITFLSEIFL	CHD6	491	Q8TD26
VFTLTKQLNTLKDLF	CEP290	1936	O15078
INTKTNLVALLADFS	FRMPD4	451	Q14CM0
TLFSIQLLDFKTSLL	CCDC73	21	Q6ZRK6
CLLLSSFQFSIQKLE	DSN1	136	Q9H410
KRLLLVDFSSQALFQ	ADGRG1	286	Q9Y653
IFQVLLLKFSQLKSS	DNAH14	806	Q0VDD8
TFAISILQQLEIEFK	EIF4A2	86	Q14240
KLAATNALLNSLEFT	KPNB1	191	Q14974
INTFTLLNFLINSKS	DONSON	406	Q9NYP3
LLNFLINSKSLVATS	DONSON	411	Q9NYP3
LSIITKDLFQVAFNR	DYNC1H1	3856	Q14204
LTVELFQITNKAISS	SLC44A3	311	Q8N4M1
FQITNKAISSAPFLL	SLC44A3	316	Q8N4M1
FLFLTTILQNFNLKS	CYP2C18	446	P33260
LASNKLQIVFDFVAS	FAF1	591	Q9UNN5
VTLLNLVLFKASDTN	FRY	1256	Q5TBA9
FLFLTSILQNFNLKS	CYP2C9	446	P11712
LVQEFTKGIQTLFLS	HELQ	746	Q8TDG4
LILFATFNEVKSQNL	CFAP69	336	A5D8W1
FKNVELLFSGLVINT	SLC31A1	51	O15431
LLLTFLAKQHTDSFQ	IPO4	1046	Q8TEX9
FNATLFALVRTALKI	CACNA1D	1546	Q01668
STTIFSLDLKLIIFQ	IFNE	16	Q86WN2
GFSQTQELQKFLFLL	OR4D1	16	Q15615
SQFSLKTAALRVFDL	MIGA1	41	Q8NAN2
SIFVIASVLKDFLRN	ARHGAP20	426	Q9P2F6
VHTNALKIVISFLLF	TAS2R13	226	Q9NYV9
LFLSAIQLTHFQKLS	TAS2R38	71	P59533
ILTNVFAILSAKNLS	UTP20	1231	O75691
LQILFSEDSTKLFVA	UTP4	441	Q969X6
SLLSIAQLFDFAKDL	UTP6	241	Q9NYH9
QFLLKSLISQTVIDS	PTAR1	241	Q7Z6K3
ILNFQNDLKVLFTSL	SYNE1	6486	Q8NF91
KDIAINLFTNVFLTT	TMEM131L	461	A2VDJ0
VLVSIKSSLPENNFF	SYNJ1	896	O43426
NERTFFLFDKTLLIT	PLEKHG3	316	A1L390
FFLVSALLINVLKVS	SLC26A8	151	Q96RN1
LQKNSSSFLVLFLIN	GPR108	106	Q9NPR9
SSFLVLFLINTKDLQ	GPR108	111	Q9NPR9
NNKFFIDTSIILFLN	GNAO1	256	P09471
LFKDLSARLVSIQSQ	SH3TC2	91	Q8TF17
LQLAENSLLAKVFIT	NHEJ1	16	Q9H9Q4
FNLSLLVTLFSQINL	SP110	76	Q9HB58
VALSTLVFENLVSFK	ABCC12	196	Q96J65
LTFTLALFIAKAALQ	URB1	1726	O60287
RLSVLSALQDTFFAK	RIPOR2	371	Q9Y4F9
IQNLKVLSVFSTLAN	SLC36A3	206	Q495N2
FLKLAQLNTFDIATK	SNX31	101	Q8N9S9
TKEFLLSLLQIFDAV	CLN5	301	O75503
FKVALFSRLVNALSE	CMKLR1	326	Q99788
FSQLKSELFLKDNSL	C12orf56	331	Q8IXR9
NLFKLLNLQSLFVTS	CLCNKA	646	P51800
KAAQIVLISLFELNT	CLASP1	1041	Q7Z460
LQFKLLTEISSAVFI	URGCP	346	Q8TCY9
FSKVANTILFFRLDI	TMX2	96	Q9Y320
VLLDLNKHTLTFFIN	TRIM67	721	Q6ZTA4
FILLFQRLQNSKTTK	CSE1L	771	P55060
LSFQAKLTFEDVAVL	ZNF250	16	P15622
FQLLLDTAQFEFILK	WASHC5	411	Q12768
VALNLFLSNKFTDAL	TTC39B	141	Q5VTQ0
SLKTLFILFRNETVD	ZCCHC3	251	Q9NUD5
QSAFKAQVSTLLTLL	TRAPPC14	206	Q8WVR3
NLAFLDILSEFSSKL	STAG2	996	Q8N3U4
IFIFTKVFLIDNLDT	FAM20B	16	O75063
KFSQLFQTLFELETE	SUGP2	346	Q8IX01
DRTLETLKIFIFNQT	TXNDC15	281	Q96J42
VKVAFSSLNLLLQTQ	VPS13C	1016	Q709C8
VKLLLFAIQRTTNFE	VPS53	341	Q5VIR6
KLEELVTISSFLNSF	UBE3B	556	Q7Z3V4
LQSAQILSFIKSNAL	ZMYM6	1031	O95789
LFDIFTLSCNLLKQA	XPO7	186	Q9UIA9
VVLNLFIALLLNSFS	SCN11A	801	Q9UI33
ASLLNLKSEEFRTFI	TBX20	241	Q9UMR3
KILFTEATRILFFNT	PSMD8	281	P48556
TFDLFSISNINRKTI	THBS2	26	P35442
SYKATIQQTLDILFL	WDR25	371	Q64LD2
FLSFTQEQQALAKVL	TLR2	541	O60603
QSLVIVLLGFKSFLS	SLFN5	531	Q08AF3
IDIKLLQFSSAFQFA	TMEM266	121	Q2M3C6
LTLSFQSRLTELQKF	ZNF836	141	Q6ZNA1
LKDVVSFLTAASFLQ	ZBTB34	96	Q8NCN2
SKLLSFVIQNAVFTL	UNC79	2221	Q9P2D8
FFKRTIALLVLAQSV	NALCN	1211	Q8IZF0
NAVLAKDALVFLNTS	MUSK	326	O15146
FKTLHFLLTEALQLL	ART1	151	P52961